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ABSTRACT OF DISSERTATION

METHODS DEVELOPMENT AND APPLICATION OF TWO-DIMENSIONAL
CHROMATOGRAPHY AND TANDEM MASS SPECTROMETRY IN PROTEOMICS
In recent years, proteomics has gained considerable attention as a complimentary
discipline to genomic research. The ability to identify, quantify, and characterize complex
mixtures of proteins expressed in an organism provides a better understanding of the
physiological processes taking place. As such, some thought has recently been given to twodimensional (2-D) LC-MS/MS as a “shotgun” approach to proteomics. By coupling 2-D
chromatographic separations to present-day quadrupole ion traps, one gains the chromatographic
peak capacity to resolve complex mixtures of peptides/proteins while performing “on-the-fly”
MS/MS analysis.
This work describes one such 2-D LC-MS/MS method for proteomics. The first three
chapters describe the background and methods development of fabricating 2-D chromatographic
capillary columns and interfacing them with an ion-trap mass spectrometer. A scheme for
packing 2-D LC capillary columns is described, and their ability to resolve complex mixtures is
assessed. In addition, scan parameters of a Finnigan LCQ Deca ion trap mass analyzer were
evaluated for proteomics applications. The effect of parameters, such as the number of averaged
scans and ion injection times, on the ability to analyze the maximum number of closely eluting
peptides while maintaining high quality MS/MS spectra is described.
The latter portion of this dissertation describes the application of 2-D LC-MS/MS to two
separate proteomic studies of human ventricular cerebrospinal fluid (CSF). The first study was a
qualitative investigation of CSF from 10 cognitively normal, elderly subjects.

A cumulative 249 CSF proteins were identified, while only 20 were found to be common among
all subjects. These results indicate extensive subject to subject variability in the CSF proteome.
However, variability associated with the 2-D LC MS/MS method itself is also addressed.
The last study describes a quantitative application of 2-D LC-MS/MS through the use of
isotope-coded affinity tags (ICAT). Here, ventricular CSF from two populations of control and
Alzheimer’s disease (AD) subjects was investigated in search of quantitative proteomic
differences. A total of 106 unique proteins were cumulatively identified as a result of this study.
However, only uracil DNA glycosylase exhibited a statistically significant decrease in the AD
subjects (Wilcoxon rank-sum, P = 0.02).
KEYWORDS: Proteomics, Multidimensional Separations, Ion-Trap Mass Spectrometry,
Cerebrospinal Fluid, Alzheimer’s Disease
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CHAPTER ONE
INTRODUCTION
PROTEOMICS BACKGROUND
In the 1990’s, the scientific community witnessed the golden years of genomic research.
Beginning with the first completed genome of the bacterium Haemophilus influenzae in 1995
(1), researchers worked feverishly to sequence the deoxyribonucleic acid (DNA) code of a
variety of organisms in an effort to understand the role of DNA in protein synthesis. In fact, the
next five years saw the completion of Caenorhabditis elegans (2), Drosophila melanogaster (3),
and even the first draft of the human genome (4). However, even with the rapid influx of
genomic data, it became increasingly evident that genomics could not account for an organism’s
functional complexity at the protein level. Although the genes of many organisms were being
sequenced and mapped at a remarkable pace, the function of their protein products was often
unknown. Additionally, genomic researchers were astonished when they discovered that vast
numbers of proteins expressed by an organism were grossly under represented by a fewer
number of genes. For example, based on the more than 100,000 unique protein products, it was
originally thought that the human genome contained as many as 120,000 genes; however, studies
revealed that 30,000-35,000 genes may be more accurate (5,6). These issues were of some
concern since it is the presence or absence of proteins that ultimately determine an organism’s
phenotype, and proteins are the primary targets for therapeutic agents.
To address these concerns, scientific effort has recently shifted from collecting genetic
data and elucidating genomic sequences to total protein analysis, giving rise to a new scientific
discipline called proteomics (7-13). The term “proteome” refers to the protein compliment of an
organism’s genome (14). In the same manner that genomics attempts to assemble a “snapshot”
of an organism’s gene sequence, proteomics seeks to assemble a comprehensive protein profile
for an organism, tissue, or cell at a particular developmental stage or under a particular set of
physiological conditions (9,15-17). Proteomics provides information such as: (i) if and when
particular proteins are translated; (ii) the relative abundance of expressed proteins; and (iii) the
post-translational modifications of proteins. While the genome is generally considered to be
static over time, protein synthesis is not. The expression of proteins from the genetic code is an
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ever-changing process, and the relative abundance of expressed proteins is heavily dictated by
the organism’s environmental and physiological status at any given time. Although mRNA
quantitiation by cDNA microarray analysis can reveal some information concerning relative
protein expression levels (18), it has been shown that mRNA levels do not always correlate well
to actual protein abundances (19). Adding to the complexity of protein expression is the ability
for proteins to be modified after translation (e.g.; phosphorylation, glycosylation, oxidation,
acylation, and methylation), giving rise to protein isoforms (20,21). Such post-translational
modifications are vital for the proteins to function correctly and for proper identification and
regulation in many cellular processes.
PROTEOMICS APPROACHES
Currently there are two methods of choice for performing proteomics analysis. Known as
“top-down” and “bottom-up” proteomics, these techniques both rely on mass spectrometry (MS)
for the analysis of complex protein analysis. However, each is very unique in its approach to
extracting proteomic information from complex protein mixtures.
Top-Down Proteomics
Top-down proteomics refers to the manner in which information is acquired through the
direct analysis of intact proteins (22-30). In this approach, proteins in a mixture are resolved,
commonly by high performance liquid chromatography (HPLC), and introduced into a mass
spectrometer via electrospray ionization (ESI). Selected precursor ions are then isolated and
thermally activated to fragment the intact protein (e.g; collision-induced dissociation (CID)
(31,32), photodissociation (33), surface-induced dissociation (34), or blackbody infrared
radiative dissociation (BIRD) (35)), resulting in a tandem (MS/MS) spectrum. Identification of
the protein is made by searching the uninterpreted MS/MS spectrum against a protein database or
by de novo analysis to determine the amino acid sequence. The top-down approach of
interrogating whole proteins provides the advantage of making the entire protein sequence
accessible for one to obtain complete characterization. However, this method does suffer from
several drawbacks. The first is inefficient protein fragmentation. Dissociative “heating”
techniques such as those mentioned above often result in the cleaving of post-translational
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modifications, a dissociation process that requires less energy than that required to break the
C−N bonds of the protein backbone. Recently, however, this problem has been alleviated with
the development of an alternative dissociation method called electron capture dissociation
(ECD). This technique produces more extensive fragmentation of large, multiply charged
proteins (36-38). Another complication with top-down proteomics stems from ESI’s
characteristic of producing multiply charged ions. Dissociation of a multiply charged protein
precursor ion produces a spectrum of several fragment ions, each having its own distribution of
charge states. Interpretation of such spectra can be a daunting task. For this reason, the mass
analyzer of choice for performing top-down proteomics is typically a Fourier transform ion
cyclotron (FT-ICR) mass spectrometer. An FT-ICR provides enough resolution to measure
spacing between isotope peaks of high mass fragments, thus leading to proper charge state
assignments and aiding in spectra interpretation. Unfortunately, FT-ICR mass spectrometers are
typically larger and more expensive than most other types of mass spectrometers.
Bottom-Up Proteomics
The proteomics approach currently drawing the most attention is that of bottom-up
proteomics. Contrary to top-down, bottom-up proteomics assembles protein information from
the analysis of peptides generated from proteolytic digests and can be carried out via two basic
schemes. The first scheme (Figure 1.1a), known as peptide mass fingerprinting, typically begins
with two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), whereby proteins in a
mixture are separated by charge (i.e.; isoelectric focusing, IEF) in the first dimension and then
separated orthogonally by size on a polymeric polyacrylamide gel in the second dimension (39).
Resolved proteins in the gel are then visualized using protein stains such as coomassie blue (40),
silver (41), or SYPRO ruby (42). Individual protein spots are excised from the gel and subjected
to proteolysis with an enzyme such as trypsin to produce small peptides that are then extracted
from the gel piece. Peptides from the digestion are then visualized using matrix-assisted laser
desorption ionization time of flight (MALDI-TOF) mass spectrometry. The resulting spectrum
is a “fingerprint” of generated peptides whose combination of masses are unique to the parent
protein. The list of peptide masses is searched against an in silico digestion of the protein
database, where the experimental peptide molecular weights are compared to theoretical peptide
molecular weights to identify the protein of interest (43).
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Figure 1.1. Two schemes for conducting bottom-up proteomics analysis. (a) The peptide mass
fingerprinting scheme begins with 2-D gel electrophoresis followed by spot picking, in-gel
digestion, MS of generated peptides (typically MALDI-TOF), and database searching. (b) The
peptide fragmentation scheme begins with direst proteolysis of protein mixture, followed by
separation of generated peptides, MS/MS of resolved peptides, and database searching.
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A second scheme for performing bottom-up proteomics is by peptide fragmentation
(Figure 1.1b). This approach begins with the direct proteolysis of a protein or protein mixture.
Generated peptides are then separated (typically by HPLC), and each peptide is subjected to
MS/MS analysis to produce a unique spectrum of peptide fragments. With the aid of
electrospray ionization (ESI), peptides in the HPLC effluent can be directly introduced into the
mass analyzer (e.g.; ion trap or triple quadrupole) allowing on-the-fly MS/MS analysis. Through
the use of modern protein database search algorithms, the MS/MS spectrum of each peptide is
correlated to computer-predicted MS/MS spectra to elucidate its amino acid sequence, thus
identifying the parent protein of interest.
Bottom-up proteomics via peptide fragmentation is made possible by the predictable
nature in which protonated peptides dissociate. Peptide fragmentation predominantly proceeds
by cleaving amide bonds along the peptide backbone, resulting in six possible types of fragment
ions (Figure1.2). Fragment ion types a, b, and c result when the positive charge resides on the Nterminal fragment, and x, y, and z ions are produced when the C-terminal fragment retains the
positive charge. The type of ions produced is largely dependent upon the dissociation technique
and the amount of kinetic energy imparted on the peptide to cause it to fragment. CID is a low
energy dissociation technique that results in predominantly b, y, and occasionally a ions. An
example of a peptide MS/MS spectrum resulting from CID in a quadrupole ion trap is provided
in Figure 1.3. CID and quadrupole ion traps will be discussed in depth later in this chapter.
Though both of these schemes are proven approaches to performing bottom-up
proteomics, each has its shortcomings. Peptide mass fingerprinting, for example, relies on 2DPAGE to isolate all proteins prior to digestion and analysis. Two-dimensional electrophoresis,
however, is a relatively labor intensive process that requires considerable time to cast gels, run
each dimension, and stain the proteins. It also lacks reproducibility, often resulting in marked
changes in protein staining and migration patterns from run to run, making comparative studies
extremely difficult. Additionally, the nature of peptide mass fingerprinting requires one-by-one
analysis of proteins. Although analyzing one protein at a time reduces the complexity of the
system by dealing only with peptides generated from a single protein, considerable time and
effort is required to excise, process, and analyze all protein spots form a 2-D gel. On the other
hand, the peptide fragmentation scheme described in Figure 1.1b is amenable to simultaneous
analysis of many peptides in a mixture. However, this scheme is only as good as the separation
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method used to resolve the peptides prior to MS/MS analysis. Most biological samples are
complex mixtures containing numerous proteins, the proteolysis of which creates an even more
complicated mixture of peptides. As such, the need arises for separation methods that are
capable of resolving thousands of peptides. Sample prefractionation or multidimensional
separations are typically required.
BOTTOM-UP PROTEOMICS TOOLS
As described in the previous section, proteomics relies largely on mass spectrometry and
the ability to rapidly obtain accurate masses of proteins and peptides, regardless of the approach
taken. However, in addition to the mass spectrometer, a variety of other instrumentation is also
necessary to resolve protein/peptide mixtures and introduce them into the mass spectrometer for
analysis. Once data is acquired by the mass spectrometer, bioinformatics tools are then needed
to parse protein databases in an effort to match the experimental data to proteins of interest. This
section will describe some key tools commonly utilized to perform successful bottom-up
proteomics via peptide fragmentation. Such implements include HPLC and multidimensional
separations, ESI, quadrupole ion trap mass analyzers, and database search algorithms. All of
which were used in this work.
HPLC and Multidimensional Separations
Developed in the late 1960’s and 1970’s, HPLC has recently found a new niche in
proteomics (44-49). HPLC is a form chromatography in which the mobile phase is pumped
through the column at high pressure to increase the efficiency of separation. Although a variety
of stationary phases have been utilized, reversed-phase HPLC is typically the method of choice
for resolving mixtures of peptides prior to MS analysis. In reversed-phase chromatography,
columns are packed with a nonpolar stationary phase such as C18, while elution is carried out
using a polar mobile phase such as acetonitrile or methanol. Peptides in a mixture are separated
in reversed-phase HPLC as described by the partitioning model (50,51). This model is based on
the equilibrium created as peptides partition between the solid hydrophobic stationary phase and
the liquid mobile phase. As the mobile phase moves down the column, peptides migrate in and
out of the stationary phase. Peptides having more hydrophobic character have higher
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equilibrium constants, thus causing them to be retained longer in the stationary phase. The
equilibrium, however, can be shifted toward the mobile phase by increasing the organic
component of the solvent. By using a gradient mobile phase of increasing organic modifier,
peptides in a mixture are separated as those with more hydrophilic character elute first from the
column and those with more hydrophobicity elute later.
Recently, the development of microflow and nanoflow HPLC has produced
chromatographic systems with flow rates compatible to direct interfacing with mass
spectrometers (i.e., µL/min and nL/min) (52-57). These systems require the use of small
diameter capillary columns. Capillary columns typically range from 15 to 30 cm having inner
diameters (I.D.) of 50 to 400 µm. In addition to offering compatible flow rates for direct mass
spectrometry, microflow and nanoflow HPLC also provide the advantage of smaller sample
volumes and increased sensitivity.
As previously mentioned, bottom-up proteomics assembles protein information via the
analysis of peptide products from proteolytic digestions. However, when dealing with a protein
mixture, enzymatic digestion produces an even more complex matrix, often containing thousands
of peptide products. Such mixtures contain more components than can be resolved by traditional
HPLC separations. The number of components that can be successfully separated by a particular
chromatographic method is dictated by the peak capacity (nc). Peak capacity is the maximum
number of resolved peaks (having a specified resolution) that can fit within the path length (i.e.;
column length) provided by a separation method. Peak capacity is described by the equation

nc =

L
4σRs

(1.1)

where L is the column length, σ is the standard deviation of a Gaussian distributed
chromatographic peak, and Rs is the resolution of separated peaks (58). However, even this
equation does not accurately describe peak capacity when dealing with real life mixtures. It
assumes the best-case scenario in which components of the mixture line up end-to-end down the
length of the column. Unfortunately, in practice, chromatographic peaks are far less ordered and
overlap even if there is sufficient column length to accommodate the peak widths of all
components. For example, it has been estimated that for a column having a capacity for 200
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peaks (nc = 200), only 37 components in a random mixture of 100 components will be
completely resolved (58).
To deal with complex peptide mixtures, multidimensional chromatographic separations
have recently come to the forefront (56,59-63). Just as 2D-PAGE utilizes both protein size and
charge to separate mixtures two-dimensionally on a polyacrylamide gel, multidimensional
chromatography also exploits more than one physical or chemical characteristic to resolve
multicomponent mixtures. Such physical/chemical characteristics may include hydrophobicity,
size, or charge. A variety of separation modes including reversed-phase, cation/anion exchange,
and size exclusion have been combined to produce multidimensional chromatographic schemes.
The coupling of reversed-phase and strong cation exchange (SCX) is one such twodimensional chromatographic technique that has found much utility in bottom-up proteomics
applications. Yates and coworkers have described a biphasic microcapillary column packed with
both SCX and C18 materials for the “shotgun” analysis of complex protein samples (64-68).
This approach is illustrated in Figure 1.4. Briefly, this method begins with loading a proteolytic
protein digestion onto the SCX portion of the column. Peptides that are not retained by the SCX
proceed to the C18 phase where they are separated via an acetonitrile gradient and analyzed
directly by MS/MS as they elute from the column. Next, a low concentration of salt is passed
through the column to elute a fraction of peptides from the SCX and onto the C18. Ammonium
acetate is used to elute peptides from the SCX as it is volatile salt and will not harm the mass
spectrometer. Peptides on the C18 are resolved by another acetonitrile gradient and analyzed by
the mass spectrometer. Another fraction of peptides are again eluted from the SCX, this time
with a higher concentration of salt, and these peptides are separated on the C18 as before. This
cycle continues until all peptides are eluted from the SCX and analyzed. This approach reduces
the number of peptides that have to be resolved by a single chromatographic method by
spreading them out over 10 to 13 reversed-phase separations.
Electrospray Ionization

The ability to directly couple HPLC to mass spectrometry was first brought to fruition
almost 20 years ago by Fenn and coworkers with the invention of ESI (69-71). Known as a
“soft” ionization technique, this method is characterized by its ability to produce a stream of ions
from liquid samples at atmospheric pressure, while producing very little fragmentation of analyte
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Figure 1.4. Schematic illustrating a two-dimensional separation of peptides using strong cation
exchange (SCX) and C18 stationary phases. (a) Sample mixture is loaded onto column. (b)
Peptides not retained on the SCX are separated and eluted from the C18 using an organic
gradient. (c) A fraction of peptides are eluted from the SCX with a low concentration of salt. (d)
These peptides are resolved on the C18 by a second organic gradient. (e) Another fraction of
peptides is stripped from the SCX using a higher concentration of salt. (f) Peptides are once
again separated and eluted from the C18 phase with an organic gradient. This cycle continues
with increasing salt steps until all peptides are eluted from the column and analyzed.
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molecules of interest within the ionization source. Though its use is now ubiquitous throughout
the biochemical field for introducing biomolecules into the mass spectrometer, ESI is still being
investigated as its exact mechanism remains to be completely understood (72-74). As such, only
a brief discussion of the electrospray process will be provided here.
The name “ESI” is somewhat of a misnomer, as the procedure does not truly “ionize”
samples. Rather, this process is a transport mechanism, for moving pre-formed ions from the
liquid phase to the gas phase. Liquid samples handled by ESI are typically composed of a
methanol/water or acetonitrile/water solvent and a small percentage of acid (e.g.; formic or acetic
acid). This solution is passed through a capillary needle and into an electrical field created by
applying several +kV to the needle relative to a counter electrode located at the entrance to the
mass spectrometer a few centimeters away from the needle tip (Figure 1.5). As voltage is
applied, charge separation of ions occurs in solution as negative ions migrate to the needle
surface and positive ions, such as protonated peptides and proteins, are driven toward the counter
electrode. This results in the formation of a cone-shaped droplet at the tip of the needle called a
Taylor cone (73). As positive charge builds up in the Taylor cone, surface tension of the solvent
is exceeded and a plume of droplets is sprayed from the cone toward the entrance of the mass
spectrometer. As the droplets travel toward the counter electrode, solvent evaporates causing a
decrease in droplet size. The desolvation process is often aided by flowing a stream of N2 gas
across the droplet plume to evaporate solvent more effectively. Reduction in droplet size
increases charge density on the droplet surface causing increased coulombic repulsion forces.
When these forces reach the Rayleigh instability limit, surface tension of the droplets is exceeded
and fission occurs, creating even smaller droplets. This process of droplet desolvation and
fissions continues until all solvent is completely removed and only gas phase ions remain.
A unique characteristic of the ESI process is the formation of multiply charged ions. A
molecule having a mass (m) of 1000 Da, for example, may have a charge (z) of 1 to 3, whereas a
50 kDa may have a charge of 30 or greater (75). Because mass spectrometry measures the m/z of
ions, this phenomenon comes as an advantage for the analysis of large molecules. Multiple
charges commonly produce an m/z below 2000, a range attainable by all types of mass analyzers.
Figure 1.6 illustrates an example of this multiple-charging effect in an ESI mass spectrum of
myoglobin.
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Figure 1.5. Schematic of a typical ESI source
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Quadrupole Ion Trap

A variety of mass analyzers have been utilized for proteomics applications, including FTICR (22-26), TOF (76-79), and triple quadrupole. However, the quadrupole ion trap (QIT) is
one mass analyzer that has recently gained considerable utility in the proteomics community. In
addition to being able to trap and store ions as the name implies, the QIT can also selectively
isolate and fragment ions all within the confines of a three-electrode system. This characteristic
along with exquisite sensitivity makes ion traps very attractive for conducting bottom-up
proteomics experiments by peptide fragment fingerprinting.
Invented in the 1950’s by Wolfgang Paul and coworkers, the QIT is an “electric field
bottle” of sorts for trapping and storing gas phase ions (80,81). Physically the QIT is comprised
of three electrodes (Figure 1.7). Two of the electrodes, called end-cap electrodes, are essentially
identical. Each has a hyperboloidal cup-like geometry and holes in the center for the
entrance/exit of ions. The third ring electrode is also hyperboloidal in shape and is sandwiched
between the two end-cap electrodes. Assembled, the quadrupole ion trap contains a trapping
volume having dimensions r0 and z0 as designated in Figure 1.7b.
To trap ions, the QIT utilizes an ac potential known as the “fundamental rf” applied to the
ring electrode to produce a saddle-shaped quadrupole field (82-85). Oscillation of the applied rf
creates a periodic inversion of the saddle field causing ions to focus at the center of the QIT.
Assuming a symmetric cylindrical trapping volume, an ion at any position in the trap will
experience the quadrupole potential (Φ) described by the following equation:

Φr,z =

(U − V cos Ωt )  r r − 2 z 2  (U − V cos Ωt )

+
2
2
2
 r0


(1.2)

where U is the dc potential applied to the end-cap electrodes, V is the fundamental rf amplitude
applied to the ring electrode, Ω is the angular frequency of the applied rf (in rad/s), r0 is the
distance between the center of the QIT and the ring electrode, and r and z are the closest
distances between the ion and the end-cap and ring electrodes, respectively. The quadrupole
potential “seen” by the ion induces a force, resulting in an acceleration of the ion proportional to
the magnitude of that force (as governed by Newton’s law).
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Figure 1.6. An ESI mass spectrum of myoglobin.
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Figure 1.7. Quadrupole ion trap. (a) Photograph of a disassembled ion trap. (b) A crosssectional schematic of a quadrupole ion trap showing the axial (z0) and radial (r0) dimensions.
Drawing adapted from (85).
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The axial and radial motion of an ion in a quadrupole field can be quantitatively
described by a second order differential equation, called the Mathieu equation (82-85). Solutions
to this equation determine the trajectories of the ion in the quadrupole field, with regions of
stable trajectories being described by parameters az and qz. They are defined as follows:

az =

qz =

4eU
2

mr0 Ω 2
2eV
2

mr0 Ω 2

(1.3)

(1.4)

where e is the electronic charge and m is the mass of the ion.
Regions of stable ion trajectories can be graphically illustrated by Mathieu stability
diagrams (Figure 1.8). Here the shaded region represents combinations of applied dc and
fundamental rf amplitudes that provide an ion with radial and axial stability. An ion of a given
mass-to-charge ratio may be manipulated throughout a-q space and still remain within the
stability region by judiciously choosing applied dc and rf voltages. Conversely, dc and rf
amplitudes can be chosen which induce an unstable trajectory, thus removing the ion from the aq stability region and eliminating it form the trapping volume. Most commercial QIT mass
spectrometers, however, operate in the absence of an applied dc component. As such, az = 0, and
the instrument is only operated on the qz axis which maximizes the m/z range that can be
successfully trapped. Operating only on the qz axis ensures that all ions are always radially
stable. The only means of making an ion unstable is to select a fundamental rf amplitude that
provides it with an unstable axial trajectory which occurs when qz = 0.908. In this event, ions are
ejected from the trap through the apertures in the end-caps and detected by the electron
multiplier.
In a typical ESI-QIT experiment, externally created positive ions are injected into the
QIT. Ion injection is achieved using a gating lens that pulses negative to attract ions to the endcap entrance and then pulses positive to stop the influx of ions once the trap is filled. Gating
time is optimized such that the number of ions allowed to enter the trap will provide the
maximum ion current without overfilling the trap and producing a space-charge effect. Once in
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Figure 1.8. Mathieu stability diagram illustrating stable ion trajectories in a quadrupole ion trap
in terms of az-qz space. Ions lying within this region are stable in both r (radial) and z (axial)
directions and reside near the center of the ion trap. Typically, ion traps are operated in the
absence of a DC potential (az = 0), in which case qz = 0.908 represents the rf amplitude at which
ions become axially unstable and are ejected from the trap. Adapted from (85).
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the trap, ions encounter helium maintained at ~1 × 10-3 torr. Collision with helium atoms
dissipates the kinetic energy of the ions, allowing them to “cool” and focus to the center of the
trapping volume. During the injection and cooling process, the fundamental rf applied to the
ring electrode is operated at an initial amplitude such that ions of a given m/z range have stable
trajectories. As previously mentioned, ions become unstable and eject from the trap at qz =
0.908. Therefore, since the mass of an ion is inversely proportional to qz (as seen in Equation
1.4), a low-mass cutoff is created for a given rf amplitude such that all masses generating qz <
0.908 remain trapped in the quadrupole field with lower m/z ions lying closer to exclusion limit
and larger m/z ions extending towards the qz axis origin.
Once the ions are cooled and focused to the center of the QIT, the fundamental rf can
then be ramped to eject ions from the trap. As the rf increases in amplitude, ions of increasing
m/z sequentially attain a qz = 0.908 and are ejected axially through the end-cap electrodes. This
is known as a mass-selective instability scan. However, it is not the only means of ejecting ions
from the trap. Ions can also be removed via resonance ejection. In this method, a supplemental
potential can be applied to the end-cap electrodes that matches the secular frequency of an ion in
the trap. This increases the ion’s kinetic energy and exaggerates its axial trajectory; ultimately
ejecting it from the trap provided the amplitude of the supplemental signal is large enough.
Resonance ejection provides a means of ejecting ions at fundamental rf voltages lower than those
required to achieve a qz of 0.908 by essentially placing ejection “holes” in qz space. The use of a
supplemental frequency provides a means of ejecting large m/z ions that otherwise may be
unable to attain the qz of 0.908, even at the maximum available fundamental rf potential.
In some circumstances, it may be desirable to obtain structural information of a particular
ionized molecule by subjecting it to MS/MS fragmentation. Such multiple-stage MS
experiments require the selective isolation of an ion having a particular m/z in the QIT prior to
the ion dissociation event. The ion to be isolated is known as the precursor ion. Precursor
isolation can be achieved by several different methods. One approach to isolating a precursor
ion is through the use of a notch waveform. In this case, a range of supplementary potential
frequencies is applied to the end-cap electrodes corresponding to the secular frequencies of all
trapped ions other than the molecular ion to be isolated. This results in the resonance ejection of
all ions but the precursor ion.
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A second isolation method is accomplished through the application of a dc potential to
the ring electrode in addition to the preexisting fundamental rf. Adding a dc component to the
ring electrode establishes a two-dimensional stability region (as in Figure 1.8) by creating a nonzero az parameter. By applying the proper combination of dc and rf potentials, the ion of interest
is brought to the apex of the stability diagram, in which case all other ions will lie outside the
stability region and will be eliminated from the trap.
The last isolation method is known as reverse-then-forward scanning. This method
begins with the application of a supplementary oscillating potential to the end-cap electrodes to
create an ejection hole at a low qz value. The fundamental rf is then scanned backwards until all
ions having a greater m/z than the precursor ion are ejected from the trap. Ions of less m/z than
the precursor are eliminated by changing the frequency of the supplemental signal to create an
ejection hole at a higher qz value and scanning the fundamental rf potential forward until all
lower m/z ions are ejected and only the precursor remains.
Once the precursor ion has been isolated in the QIT, it is then subjected to collisionally
induced dissociation (CID) to fragment it into product ions. Previously it was illustrated how the
increased kinetic energy of ions during resonance excitation is used to induce axial instability
and eject them from the trap. Similarly, CID utilizes resonance excitation to increase the kinetic
energy of the precursor ion. However, in this process the supplemental potential applied to the
end-caps is attenuated such that the axial trajectory of the precursor ion remains stable. This
causes low-energy collisions with the helium damping gas resulting in ion dissociation rather
than ion ejection. Following CID, product ions can either be scanned out of the trap to be
detected by the electron multiplier or recycled through isolation and dissociation steps to perform
an MSn experiment.
Database Search Algorithms

As has been illustrated thus far, peptide fragmentation can be accomplished through CID
using a quadrupole ion trap mass spectrometer, typically producing an MS/MS spectrum
containing a series of b and y ions. However, the nontrivial task of elucidating the amino acid
sequences from such MS/MS spectra still remains. This step is essential for identifying the
source proteins from which the proteolytic peptides originated. Historically, the interpretation of
peptide MS/MS spectra has been accomplished by de novo sequencing. This method requires
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measuring mass differences between product ions and correlating them to the masses of amino
acid residues. If, for example the mass between a y3 and y4 ion is 115.1 Da, this difference
corresponds to proline. If a peptide fragments to give a complete series of a one type of product
ion (i.e; a, b, c, x, y, or z), then it would be possible to identify the entire amino acid sequence by
de novo sequencing. However, this is seldom the case. An MS/MS spectrum typically contains
a few types of these ions, making de novo sequencing very difficult without prior knowledge of
the ion types. Also, an MS/MS spectrum rarely contains a complete series of any one type of
product ion (at a suitable signal-to-noise), adding to interpretation difficulties.
To overcome the quandaries associated with de novo sequencing, research groups have
recently been taking advantage of modern database searching algorithms for bottom-up
proteomics applications (68,86-90). Rather than calculating product ion mass differences to
determine amino acid sequences as in de novo sequencing, these programs employ patternmatching logic to compare experimental MS/MS spectra to predicted spectra of database
peptides. Currently two such database searching algorithms are at the forefront of proteomics:
Mascot (91) and SEQUEST (92). Here a brief overview of the SEQUEST algorithm will be
discussed, as it is database searching program used throughout this dissertation.
As mentioned above, SEQUEST uses a pattern-matching approach to compare
experimental MS/MS spectra of peptides to computer-predicted spectra (92). This strategy is
represented in Figure 1.9. The analysis begins with an experimentally acquired MS/MS
spectrum. This spectrum is typically in the form of an electronic file generated by the data
acquisition software of the mass spectrometer. From this electronic file, the computer obtains
the mass of the precursor ion and a list of observed product ions. The user specifies the
proteolytic enzyme used to generate the peptides, any potential post-translational modifications,
and the protein database to be searched. The algorithm first performs an in silico digestion of all
proteins in the specified database using the enzyme noted by the user, creating a virtual database
of peptides. This database is then searched to identify peptides whose molecular weights match
that of the precursor ion (within a given mass tolerance), and a list of prospective peptide
matches is compiled. To evaluate the list of potential peptide matches, the algorithm generates
an MS/MS spectrum prediction for each peptide. This is done by calculating the m/z values of
predicted fragment ions based on the amino acid sequence using the formulas as follows:
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bn = ∑ an + 1

(1.5)

yn = MW − ∑ an

(1.6)

where an is the mass of the amino acid, MW is the molecular weight of the precursor ion, and bn
and yn are the molecular weights of the b and y ions, respectively. Next, the predicted spectra are
compared to the raw MS/MS spectrum. Provided the amino acid sequence fits the user-defined
mass tolerance, each peptide prediction is ranked by score (Sp), based on the presence/absence of
predicted product ions in the experimental spectrum using the following equation:
S p = (∑ im )ni (1 + β )(1 + ρ ) / nt

(1.7)

In this relationship, ni represents the number of predicted fragments that ions in the experimental
spectrum, im are their associated abundances, β is incremented for each consecutive fragment ion
matched in an ion series, and the ρ component is incremented for each immonium ion that is
present in the spectrum along with its associated amino acid: His, Tyr, Trp, Met, or Phe.
The top ranked, typically the first 500, amino acid sequences identified are then subjected
to further interrogation by a cross-correlation analysis to generate a final cross-correlation score
and ranking of the sequences (92). Briefly, correlation analysis calculates the coherence of two
continuous signals by translating one signal across the other using the following equation:

C xy =

+∞

∫ x(t )y(t + τ )dt

(1.8)

−∞

where x(t) and y(t) are two continuous signals and τ is the displacement value, which is a
measure of the offset between the two signals during translation. If x(t) and y(t) are truly the
same, then the correlation function should maximize at τ = 0. In the case of two discrete input
signals, such as that of an experimental spectrum and a predicted spectrum, the cross correlation
formula takes the following form:
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n −1

Rτ = ∑ x[i ]y[i + τ ]

(1.9)

i −0

where xi and yi are the predicted and observed spectra, respectively, and τ is again a displacement
value. Cross-correlation analysis is performed by fast Fourier transformation of the two data
sets. The resulting cross-correlation values for each amino acid sequence are calculated using
the correlation function for the case when τ = 0. The final scores are obtained by normalizing
the cross-correlation values to 1.0.
An unambiguous identification of the amino acid sequence is made when a +1, +2, or +3
charged peptide yields a cross-correlation score greater than or equal to 1.8, 2.5, or 3.5,
respectively. The cross-correlation score of the peptide must also have a difference of at least
0.1 from the next ranked sequence (68). The development of supplemental computer programs
such as DTAselect and Contrast (93), has greatly simplified the filtering of database search
results and the comparison results between experimental datasets.
STATEMENT OF RESEARCH

This chapter has provided a general background of proteomics and presented current
approaches to proteomics analysis. It has also covered several common instrumental and
software tools for bottom-up proteomics applications. Two-dimensional separations and
quadrupole ion traps mass analyzer were given emphasis, as they were utilized for the work
contributing to this dissertation.
The remainder of this dissertation is divided into two major parts: 1.) methods
development of a two-dimensional chromatography technique (Chapter 2) and the quadrupole
ion trap (Chapter 3) for bottom-up proteomics, and 2.) the application of these techniques to the
proteomics analysis of human ventricular cerebrospinal fluid (CSF) (Chapters 4 and 5).
Chapter 2 focuses on the development of a method for packing fused silica capillary
columns. Two packing techniques, hydraulic and pneumatic, were investigated. The
performance characteristics of fabricated reversed phase capillary columns were evaluated. A
method for generating two-dimensional capillary columns is also presented.
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Chapter 3 describes the optimization of a quadrupole ion trap mass spectrometer for
bottom-up proteomics applications. Instrumental parameters such as the number of averaged
scans and ion injection times were evaluated to determine those that produce the highest quality
spectra and, therefore, the best protein database search results.
Chapter 4 describes the application of the two aforementioned techniques (twodimensional HPLC and quadrupole ion trap mass spectrometry) to the proteomics analysis of
ventricular CSF. More specifically, the CSF from 10 neurologically normal, elderly subjects was
subjected to bottom-up proteomics analysis for a qualitative investigation of CSF proteins. The
reproducibility of the two-dimensional chromatographic approach is evaluated.
Finally, Chapter 5 presents a quantitative proteomics investigation of ventricular CSF
from control and Alzheimer’s disease (AD) subjects. Through the use of isotope-coded affinity
tag (ICAT) technology in conjunction with two-dimensional separations, differences in protein
abundance between control and AD ventricular CSF were investigated.
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CHAPTER TWO
DEVELOPMENT OF A PACKING SCHEME FOR
TWO-DIMENSIONAL HPLC COLUMNS
INTRODUCTION

Since the advent of electrospray ionization (ESI) (69-71), the combination of liquid
chromatography and mass spectrometry has become a well-established and routine approach for
the identification and characterization of peptide and protein mixtures (52-57). Considering the
ability of LC to purify, concentrate, and separate components of mixtures, and the powerful mass
determination capabilities of modern mass analyzers, it is not surprising that LC-MS has found
widespread utility in proteomics applications.
A recent movement toward microflow and nanoflow HPLC systems has brought capillary
columns to the spotlight (52-57). Capillary columns provide the added advantages of increased
sensitivities and reduced solvent and sample consumption (94,95). A major downside of
capillary columns, however, is cost. A commercially manufactured reversed phase capillary
column of 15 cm in length typically ranges from $400-$600. Considering the increased
susceptibility of capillary columns to clogging compared to traditional HPLC columns of larger
bore sizes, routine analysis of crude biological mixtures can quickly become an expensive task.
As such, the development of an in-laboratory capillary packing scheme is extremely attractive.
In addition to being economically advantageous, the ability to fabricate capillary columns inhouse would provide the benefit of being able to custom tailor columns to experimental needs.
One could envision endless combinations of column lengths, diameters, and stationary phases as
suited for the experiment at hand.
An assortment of capillary column packing procedures has been presented in literature.
These include slurry (96-100), supercritical carbon dioxide (101,102), and dry packing
techniques (103,104), with slurry packing being the most common. Slurry packing procedures
are typically either hydraulically or pneumatically driven. Hydraulic packing methods usually
employ a solvent delivery system such as an HPLC pump to deliver solvent through a reservoir
containing the slurry and carry the particle suspension to the capillary. Pneumatic packing
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devices, on the other hand, typically use pressurized helium to displace the slurry from a pressure
cell and drive it into the capillary column.
Regardless of the packing method, capillary columns have the same general architecture
of a hollow length of tubing and an end frit. Construction begins with small-bore tubing,
typically 150-800 µm I.D. for microflow applications (2-20 µl/min) or 20-100 µm I.D. for
nanoflow applications (0.1-1 µL/min) (105). Although tubing materials such as PEEK (106) and
glass-lined stainless steel (107) have been used, fused silica is commonly the material of choice
due to its flexibility and optical transparency. Capillary columns having particulate stationary
phases require an end frit to retain the particles within the column while allowing solvent to pass.
Stainless steel screens(108), porous ceramics (109), glass fiber filters (110), and sintered silica
particles (111) have been used as frits.
Chromatographic column performance is typically characterized by column efficiency.
The efficiency of a given column is quantitatively described by the number of theoretical plates
(N), and can be calculated by

 t
N = 5.54 R
W
 1 2






2

(2.1)

where tR is the retention time of an eluted compound, and W1/2 is the chromatographic peak width
at half-height. From this information and the known column length (L), the height of a
theoretical plate (H) can be calculated as follows:

H =

L
N

(2.2)

However, to perform an absolute comparison between columns of different physical
characteristics (i.e.; length, diameter, stationary phase type, and particle size), a dimensionless
parameter, reduced plate height (h), is sometimes used. Reduced plate heights provide a
normalized view of column efficiencies and is calculated by
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h=

H
dp

(2.3)

where dp is the mean diameter of the packing particles. Columns that produce h < 3 are
considered to be well packed columns (112).
As discussed in Chapter 1, considerable attention has recently been given to the
development of multidimensional chromatographic separations (56,59-63). The increased
interest lies in the need for separation methods capable of resolving complex mixtures of
peptides/proteins for proteomics applications. Traditional single dimension chromatographic
techniques lack the resolving power to separate large numbers of compounds typically associated
with raw biological fluids or whole cell lysates. Furthermore, bottom-up proteomics makes these
systems even more complex by subjecting them to proteolytic digestion prior to analysis. As
such, many research groups have been coupling two or more chromatographic modes of
separation to increase peak capacity, thus increasing the number of components that can be
resolved.
Yates and coworkers have demonstrated one such multidimensional chromatographic
method for separating complex mixtures of peptides (64-68). They described two stationary
phases (SCX and C18) packed on top of one another inside an ESI emitter to produce an
orthogonal 2-D separation method capable of separating peptides by charge then hydrophobicity.
One noteworthy characteristic of their approach was that both stationary phases were contained
within as single column. This eliminated the need for conducting off-line fractionation or
intricate arrangements of plumbing and switching valves as would have been the case if the two
dimensions were performed independently of one another.
This chapter describes the development of a method for packing capillary columns,
eventually leading to the construction of a 2-D chromatographic scheme having a single-column
architecture. Two slurry packing methods, hydraulic and pneumatic, are qualitatively assessed.
(Note: for the purpose of this discussion, “hydraulic” and “pneumatic” packing refer to methods
that utilize a liquid pumping system and pressurized gas, respectively, to deliver the packing
slurry to the capillary.) The procedure for fabricating a 2-D (biphasic) capillary column is
presented. The ability of the 2-D column to resolve a standard mixture of BSA tryptic peptides
is evaluated and compared to that of a traditional reversed phase (1-D) separation.
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EXPERIMENTAL
Materials

HPLC grade water, acetonitrile (ACN), and formic acid were purchased from Fisher
Scientific (Fair Lawn, NJ). Bovine serum albumin (BSA), [β-Asp1]-angiotensin II, [Arg8]vasopressin, uracil and ammonium acetate (NH4HCO3) were obtained from Sigma Chemical Co.
(St. Louis, MO), while ethyl 2-chlorobenzoate was purchased from Aldrich Chemical Co.
(Milwaukee, WI). A synthetic BSA tryptic peptide, HLVDEPQNLIK, was synthesized by
Michael Russ of the University of Kentucky Macromolecular Facility. Fused silica capillary
tubing (320 µm I.D. × 435 µm I.D.) was a product of Polymicro Technologies (Phoenix, AZ).
Bulk stationary phase packing material (5µm Macrosphere 300 C18 and 10 µm Partisil SCX) as
purchased from Alltech Associates, Inc, (Deerfield, IL), while 3 µm PolymerX RP-1, a
polystyrene divinylbenzene packing material, was obtained by unpacking a 150 × 4.1 mm
column purchased from Phenomenex (Torrance, CA). Additional LC accessories, including zero
dead volume (ZDV) unions, 2-µm stainless steel frits, and PEEK tubing were obtained from
Upchurch Scientific (Oak Harbor, WA).
Capillary Column Construction

All capillary columns were constructed as illustrated in Figure 2.1. In short, a 2-µm
stainless steel frit was placed in a ZDV union. Next, a length of fused silica tubing (typically 3040 cm) was given clean, square cuts at both ends using the SGT Shortix fused silica cutter
(Upchurch Scientific, Oak Harbor, WA). One end of the fused silica tubing was threaded
through a 3-cm piece of 1/16 in. O.D. × 0.020 in. (500 µm) I.D. PEEK tubing, and the assembly
was placed in the ZDV union, such that the end of the fused silica and PEEK sleeve butted flush
against the frit. The silica tubing and PEEK sleeve were held in place using a 1/16 in. stainless
steel ferrule and nut. The nut was tightened until the PEEK sleeve tightly pinched the fused
silica capillary.
Hydraulic Column Packing

A rudimentary packing reservoir was constructed using 1/8 in. stainless steel tubing and
fittings as illustrated in Figure 2.2. The capillary column assembly was connected to one end of
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Figure 2.1. Schematic of a fused silica capillary column and end frit assembly secured with a
zero dead volume union.
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Figure 2.2. Photograph of slurry reservoir for hydraulic packing of capillary columns.
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the reservoir, while the other end was connected to the output of a µLC-500 Micro Flow Pump
(Isco, Inc.; Lincoln, NE) filled with 90% ACN. A packing slurry of Macrosphere 300 C18, 5-

µm material (10 mg/mL) was prepared in 2 mL of 90% ACN. The slurry was sonicated for ~15
s and transferred to the packing reservoir. The syringe pumps were operated at a constant
pressure of 3000 psi to flow solvent through the reservoir/column assembly. Solvent was
pumped until a 15-cm bed was packed in the capillary. The reservoir/column assembly was
sonicated intermittently throughout the packing process. Following packing, the column was
conditioned for ~30 min with 50% ACN/ 50% formic acid (0.1%) flowing at 4 µL/min.
Pneumatic Column Packing

A pneumatic pressure cell was custom fabricated in-house for packing capillary columns
(Figure 2.3). The stainless steel cylindrical pressure cell was 6.1 cm tall and 3.8 cm in outer
diameter. The bore of the cell measured 2.8 cm deep and 1.3 cm in diameter to accommodate a
0.5 dram glass vial. The lid was drilled, tapped, and fitted with a stainless steel 1/8 in. National
Pipe Thread (NPT) male-to-1/16 in. ZDV fitting. Four radially distributed, countersunk
socketcap screws secured the lid the cell body, while a rubber o-ring provided an airtight seal. A
compressed helium inlet port was drilled through the side of the cell and fitted with a stainless
steel 1/8 in. NPT-to-Swagelok adapter, 1/8 in. tubing, and a 3-way Swagelok valve. In this
manner, the cell could be pressurized by opening the valve to a compressed helium cylinder, or
vented by opening the valve to atmosphere.
A packing slurry of 3-µm PolymerX RP-1 was prepared to 10 mg/mL in 90% ACN in a
0.5 dram glass vial. A micro magnetic stir bar was added to the slurry. The vial was sonicated
for ~15 s to suspend particles and placed inside the pressure cell. The end of the capillary
column assembly was threaded through the ZDV fitting in the lid of the pressure cell and fixed in
place with a nut and PEEK ferrule such that the fused silica tubing dipped into the packing slurry
within the cell. All nuts and bolts were securely tightened to create an airtight seal. The cell was
pressurized to 1200 psi until a packed bed of desired length was achieved, typically 15 cm for
reversed phase columns. Following packing, the column was conditioned for 30 min by
connecting it to an HPLC pump and flowing 50% ACN with 0.1% formic acid at 4 µL/min. To
enhance the conditioning step, the column was submerged in an ultrasonic bath and sonicated for
~55 s to obtain a tightly packed bed.
32

To
Column
Assembly

a

Compressed
Helium
1200 psi

1/16 in. Nut
and PEEK
Ferrule

Fused Silica
Tubing
Screws

b
1/2 Dram Vial
w/ Packing Slurry

O-Ring

Compressed
Helium
1200 psi

Magnetic
Micro Stir
Bar

Figure 2.3. (a) Photograph and (b) cross-sectional schematic of slurry pressure cell for
pneumatic packing of capillary columns.
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Two-dimensional capillary columns were fabricated in a similar manner. First, 15 cm of
the PolymerX RP-1 reversed phase material was packed using the pneumatic packing cell and
condition as just described. Following conditioning, the column was returned to the pressure cell
to pack 5 cm of Partisil SCX (10 µm) on top of the reversed phase material. Once again, the
column was reconnected to an HPLC pump and conditioned for 30 min with 50% ACN and
0.1% formic acid at 4 µL/min followed by sonication for ~15 s.
Evaluation of Column Performance

Hydraulically packed reversed phase Macrosphere 300 C18 columns were evaluated by
injecting a 5-µL mixture of vasopressin and angiotensin II (~1 ng/µL of each peptide).
Pneumatically packed columns were evaluated using 5 µL of the synthetic BSA peptide,
HLVDEPQNLIK (~10 ng/µL) and BSA tryptic digest (~100 ng/µL). Column efficiencies of
pneumatically packed PolymerX RP-1 reversed phase capillary columns were also evaluated by
injecting 500 nL of a mixture containing 1 mM uracil and ethyl 2-chlorobenzoate. Separations
were carried out using an LC Packings Ultimate capillary LC quaternary pump (San Francisco,
CA). Mobile phase A was 0.1% aqueous formic acid and mobile phase B was I +0.1% formic
acid. For separations of peptides, the HPLC system was equipped with a 5-µL injection loop,
and a linear gradient of 5-95% B was delivered to the capillary column over 40 min at 3 µL/min.
For evaluating column efficiencies using ethyl 2-chlorobenzoate, the injector was equipped with
a 500 nL injection loop, and separations were carried out isocratically using 30% A and 70% B
at 3 µL/min. Column effluent was directly electrosprayed at 4.0 kV into a Finnigan LCQ Deca
quadrupole ion trap mass spectrometer (Thermo Finnigan, San Jose , CA). The ESI source was
provided with 43 arbitrary units of helium sheath gas flow to aid in the desolvation process. For
the analysis of angiotensin II, vasopressin, and the synthetic BSA peptide, full scan mass spectra
of eluting peptides were acquired from m/z 400-2000. Each full scan mass spectra consisted of 3
averaged scans with maximum ion injection times of 300 ms. For the analysis of the BSA tryptic
digest, however, MS/MS spectra were acquired in a data-dependent fashion by first acquiring a
full MS scan from m/z 150 to 2000 followed by a MS/MS scan between m/z 150 and 2000 of the
most intense ion of the previous full MS scan. Each full scan was a product of 3 averaged scans
having maximum injection times of 300 ms, while each MS/MS consisted of 5 averaged scans
having 500 ms maximum injection times.
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The 2-D columns were evaluated using the tryptic BSA digestion mixture. The
chromatographic setup for 2-D chromatographic separations was quite different. Mobile phase
A was 0.1% aqueous formic acid, mobile phase B was ACN + 0.1% formic acid, mobile phase C
was 300 mM ammonium acetate, and mobile phase D was 5% ACN + 0.1% formic acid. A
single 2-D separation consisted of 13 individual chromatographic profiles. Profiles 1 to 11
began with a 5-minute (t = 0-5 min) isocratic salt step consisting of x% C (x = 0, 1.67, 3.33, 5.00,
6.67, 10.00, 13.33, 16.67, 33.33, 50.00, 75.00) and (100 – x)% D. This was followed by a 2minute wash (t = 5-7 min) with 95% A and 5% B to equilibrate the column. Next, a linear
gradient was pumped from 95 to 50% A with 5 to 50% B (t = 7-55 min) followed by a steeper
linear gradient from 50 to 20% A with 50 to 80% B (t = 55-75 min). The column was returned
to initial conditions with a linear gradient from 20 to 95% A with 80 to 5% B (t = 75-80 min) and
equilibrated for 5 minutes (t = 80-95 min) at 95% A and 5% B before continuing to the next
chromatographic profile. Chromatographic profiles 12 and 13 differed only in their initial salt
steps. Profile 12 began with 100% C for 15 min, and profile 13 consisted of a manual 20-µL
injection of 3 M ammonium acetate prior to the described organic gradient. Tandem MS data
was acquired in the same data-dependent fashion as described above.
MS/MS data acquired from separations of BSA digest were subjected to protein database
searches. Using the SEQUEST database search algorithm, the MS/MS spectra of eluted peptides
were searched against a Bos tuarus sub-database of the NCBI non-redundant protein database.
Peptide matches were considered to be unambiguous identifications if the associated crosscorrelation score were ≥ 1.9 for singly charged peptides, ≥ 2.5 for doubly charged peptides, and

≥ 3.5 for triply charged peptides (68).
RESULTS AND DISCUSSION

In these experiments, two methods for packing capillary HPLC columns were explored.
The first method was a hydraulic approach that utilized high-pressure solvent flow from a
syringe pump to transfer the packing slurry to the capillary column. The second pneumatic
method used pressurized helium to force the packing slurry from a pressure cell to the capillary.
Both methods were evaluated, and the performance of the fabricated capillary columns was
accessed.
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Using the hydraulic packing scheme to pack a 15-cm C18 column proved to be much
more difficult than was anticipated. Although columns were successfully packed with this
method, the time required to do so was lengthy. Inefficient transfer of the slurry from the
reservoir to the capillary often resulted in several hours of labor to pack just a single column.
This was, in part, due to settling of particles in the slurry reservoir. Keeping a homogenous
suspension in the reservoir proved difficult, even with the aid of sonication. The geometry of the
primitive slurry reservoir probably added to this complication by trapping particles in sharp
corners of the reservoir’s interior. It has been shown that the reservoir geometry is extremely
important (113) in achieving efficient packing. Additionally, as particles were displaced from
reservoir with incoming solvent, the slurry concentration in the reservoir became diluted and the
rate packing was further decreased over time.
Despite the challenges of the hydraulic method of packing capillaries, the resulting
columns did exhibit acceptable chromatographic characteristics. Figure 2.4, for example, shows
an extracted ion chromatogram for a standard mixture of angiotensin II and vasopressin. Each
peptide exhibited a near-Gaussian peak with good chromatographic resolution from one another.
Unlike the hydraulic approach, the pneumatic packing scheme provided an efficient
means of packing capillary columns. The use of compressed helium provided an even flow of
particles to the column and eliminated the dilution effect exhibited by the hydraulic packing
method, thus maintaining a constant slurry concentration in the pressure cell throughout the
packing process. Additionally, the magnetic stirrer proved to be extremely useful in sustaining a
homogenous slurry suspension. As a result, the pneumatic packing method was typically
capable of packing 15 cm of reversed phase material in ~20 min.
Three 15-cm pneumatically packed PolymerX RP-1 columns were evaluated for
chromatographic performance. Chromatograms of synthetic BSA tryptic peptide,
HLVDEPQNLIK, were acquired with all three columns (Figure 2.5). All three chromatograms
exhibited narrow Gaussian peaks for the eluted peptide having an average W1/2 of 0.21 ± 0.04
min. Using uracil, an unretained compound, to determine the “dead time” of the
chromatographic system, theoretical plate numbers and reduced plate heights were calculated
using Equations 2.1 and 2.3 (Table2.1). In all three cases, h was well below 3, indicating wellpacked columns.
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Figure 2.4, Extracted ion chromatogram of vasopressin (M+H = m/z 1046.5) and angiotensin II
(M+H = m/z 1084.5) acquired from a hydraulically packed 320 µm I.D. × 15 cm, 5 µm
Macrosphere 300 C18 capillary column.
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Figure 2.5. Extracted ion chromatograms for synthetic BSA peptide, HLVDEPQNLIK, from
three pneumatically packed 320 µm I.D. × 15 cm, 3 µm PolymerX RP-1 capillary columns.
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Table 2.1. Chromatographic efficiencies of three pneumatically packed PolymerX RP-1 capillary
columns

Number of Theoretical

Theoretical Plate

Reduced Plate

Plates (N)

Height (H), µm

Height (h)

Column 1 (15.5 cm)

61,467

2.52

0.84

Column 2 (15.1 cm)

32,210

4.69

1.56

Column 3 (15.0 cm)

20,858

7.45

2.45

38,178 ± 20,952

4.89 ± 2.47

1.62 ± 0.81
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As reported, these calculated efficiencies were somewhat deceiving. Typically,
theoretical plate numbers are determined from separations performed under isocratic conditions.
Solvent gradients tend to compress peaks as a result of chromatographic focusing of compounds
at the head of the column, thus exaggerating column efficiency. Therefore, the number of
theoretical plates was recalculated for all three columns under isocratic conditions using ethyl 2chlorobenzoate. An example chromatogram is shown in Figure 2.6. An average efficiency of
3196 ± 752 N/m (plates/meter) was calculated from triplicate runs on each column. This value
was surprisingly low, especially in the light that a similar commercial column (300 µm I.D ×.15
cm, 3 µm PepMap C18) from LC Packings is reported to have approximately 100,000 N/m.
To put this into perspective, it must be understood that although the number of theoretical
plates is a quantitative measure of band broadening that occurs during a chromatographic
separation, it is not restricted to intrinsic characteristics of the column. Extra-column volumes,
for example, are also a major contributor to band broadening. These are volumes within the
HPLC system (between the injector and detector) that are unoccupied by the packing bed, but
effect the chromatographic separation. Components that potentially add to extra-column
volumes include the injector, connecting tubing, and connecting fittings. The setup utilized to
perform these separations had considerable extra-column volumes, both pre-column and postcolumn. It was estimated that the connecting tubing from the injector located on the HPLC
pumps to the head of the column contributed at least 10.5 µL of extra-column volume, while the
frit assembly and transfer capillary from the tail of the column to the ESI source accounted for
approximately 0.5 µL. At first, these values may seem insignificant; however, these volumes
provide a total of more than 3.5 minutes of flow (at 3 µL/min) over which diffusion and mixing
can occur. Unfortunately, due to the size and orientation of the pumps and ESI source, arranging
the instruments to minimize extra-column volumes was less than ideal (Figure 2.7). However, to
evaluate the impact of the extra-column volumes, a sample injector was inserted closer to the
head of the column, such that pre-column extra-column volume was reduced to roughly 3 µL,
and the experiment was repeated (Figure 2.8). As a result, an increase of approximately 2000
theoretical plates was achieved. This indicated that the decreased number of theoretical plates,
as calculated, might not be due to the pneumatically packed columns themselves, but rather a
factor of the HPLC plumbing.
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Figure 2.6. Chromatogram of uracil (t = 5.95 min.)and ethyl 2-chlorobenzoate (t = 12.12 min.)
obtained from pneumatically packed 320 µm I.D. × 15 cm, 3 µm PolymerX RP-1 capillary
column under isocratic conditions.
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Figure 2.7. A picture showing the HPLC-MS instrumental setup.
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Figure 2.8. Chromatogram of uracil (t = 3.22 min.) and ethyl 2-chlorobenzoate (t = 9.30 min.)
obtained from pneumatically packed 320 µm I.D. × 15 cm, 3 µm PolymerX RP-1 capillary
column under isocratic conditions after reducing extra-column volumes.
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This was further supported by a chromatogram supplied by LC Packings (Figure 2.9a).
This chromatogram showed the elution of BSA peptide, HLVDEPQNLIK (as used above), from
a 75 µm I.D. × 15 cm, 3 µm PepMap C18 column using an ACN/water gradient. This data
showed that the peak shape and width (~ 1 min. at base) were surprisingly similar to those shown
acquired from the pneumatically packed columns (Figure 2.9b). As mentioned previously,
solvent gradients tend to compress peak widths by allowing compounds to focus at the head of
the column under low concentrations of organic solvent before migrating down the column at
higher organic levels. In effect, this eliminates band broadening due to pre-column extra-column
volumes. As such, the comparison of both chromatograms in Figure 2.9 indicates that the
pneumatically packed columns demonstrate comparable performance to commercially available
columns once the effect of extra-column volumes is eliminated from the system.
To evaluate the ability to resolve a more complex mixture of peptides, a BSA digest was
run on a pneumatically packed PolymerX RP-1 column and MS/MS data was acquired from the
eluting peptides. The resulting chromatogram is shown in Figure 2.10. A protein database
search of the MS/MS data yielded the unambiguous identification of 16 unique BSA peptides
totaling 16.8% amino acid coverage. Closer inspection of the chromatogram revealed several
coeluting chromatographic peaks. Failure to resolve these peaks may have prevented the
identification of several more BSA peptides.
The 2-D capillary column was evaluated using the same BSA digest. As performed, the
2-D chromatographic experiment yielded 13 individual chromatograms, each containing a
fraction of BSA peptides (Figure 2.11). The MS/MS data acquired from all 13 chromatographic
runs were searched against the protein database as before. This time, however, the search
produced unambiguous identifications for 26 unique BSA peptides, 62% more than was possible
with the reversed phase (1-D) column alone. These peptides accounted for 21.1% amino acid
coverage of the BSA protein. Although the 2-D separation led to the identification of 10 more
BSA peptides, 21.1% coverage still seemed rather low. Since the majority of all the peaks in all
13 chromatograms appeared to be well resolved, it was speculated that inefficient proteolysis
was responsible for the low protein coverage rather than a lack in resolving power. In fact,
inspection of a few of the broad peaks (in Figures 2.11k and 2.11l, for example) revealed the
presence of large protein fragments (> 5,500 Da), further substantiating the argument of poor
protein digestion.
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Figure 2.9. Chromatogram of BSA peptide, HLVDEPQNLIK, acquired from (a) a commercial
LC Packings 75 µm I.D. × 15 cm, 3 µm PepMap C18 capillary column, and (b) a pneumatically
packed 320 µm I.D. × 15 cm, 3 µm PolymerX RP-1 capillary column.
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Figure 2.10. Chromatogram of BSA tryptic digest separated on a 15 cm × 320 µm PolymerX RP1 capillary column.
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Figure 2.11. Thirteen chromatograms from a single 2-D chromatographic separation of a BSA
tryptic digest using (a) 0, (b) 5, (c) 10, (d) 15, (e) 20, (f) 30, (g) 40, (h) 50, (i) 100, (j) 150, (k)
225, (l) 300 , and (m) 3000 mM ammonium acetate to elute peptides from the SCX dimension.
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CONCLUSIONS

In this chapter, two techniques for slurry packing capillary columns were presented,
hydraulic and pneumatic. Of the two, pneumatically-driven packing was superior to hydraulic in
our hands. This was based on the qualitative assessment that the pneumatic setup was much
easier to operate and packed columns much faster than the hydraulic method, capable of
producing three 15-cm columns in an hour. Inefficient transfer of the slurry to the capillary was
most likely a factor of the primitive slurry reservoir design. Pneumatically packed PolymerX
RP-1 capillaries produced surprisingly few numbers of theoretical plates as calculated for ethyl
2-chlorobenzoate under isocratic conditions. However, investigation of the HPLC system
revealed considerable extra-column volumes (rather than the column itself), was responsible for
excessive band broadening, and thus lower chromatographic efficiencies. The presence of precolumn extra-column volumes identified in the HPLC system was not a concern in this work, as
the ultimate goal was to generate functional 2-D capillary columns. The 2-D method would
eliminate band broadening due to extra-column volumes by first capturing peptides on the SCX
and then refocusing them onto the head of the reversed phase under solvent gradient conditions.
A method for constructing 2-D columns was also discussed. Using the pneumatic
packing scheme to pack 5 cm of SCX on top of a 15-cm bed of reversed phase material, a 2-D
column in a single capillary architecture was produced. Using a BSA tryptic peptide mixture,
the 2-D column demonstrated an increase in peak capacity by resolving and identifying 26
unique BSA peptides. This was 62% more than was identified using a 1-D reversed phase
capillary column. This preliminary data indicated that the 2-D capillary column is capable of
resolving mixtures of greater complexity than traditional reversed phase separations.
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CHAPTER THREE
FACTORS THAT EFFECT ION TRAP DATA-DEPENDENT
MS/MS IN PROTEOMICS
INTRODUCTION

In recent years, the bottom-up approach to proteomics has gained much notoriety in the
scientific community (11,49,60,64,67,68,114-122). This approach begins with the proteolysis of
a protein or mixture of proteins to generate an even more complex mixture of peptides. These
peptides are isolated, subjected to direct MS/MS analysis, and identified via protein database
searching algorithms that match the acquired MS/MS spectra to computer-predicted spectra and
lead to the identification of the parent proteins (91,92). However, the challenge of accurately
identifying all proteins present in a mixture relies on the ability to sufficiently resolve all
peptides resulting from the enzymatic digestion while simultaneously acquiring high quality
MS/MS spectra which will lead to proper ion assignments and protein correlations by the
database searching algorithm.
To address the problem of resolving such complex mixtures of peptides, some research
groups have employed multidimensional HPLC techniques (49,60,61,64,67,68,118-125). In
these schemes, peptides are separated by utilizing two or more of their physical properties such
as hydorophobicity, charge, and size. Moving to multiple dimensions of separation modes
increases peak capacity (i.e.; the maximum number of components that can resolved over a given
separation length). An increase in chromatographic peak capacity translates into a greater
number of peptides that can be resolved and thus interrogated by MS/MS analysis.
Multidimensional separations undoubtedly have greatly increased the number of proteins that
can be identified in complex mixtures; however, these techniques do have their limitations, and
peak capacity is still an issue.
Bottom-up proteomics on complex mixtures would not be possible without the existence
of instrument decision-making algorithms that can automatically perform MS/MS experiments
on precursor ions selected from a previously acquired full scan. The use of such algorithms is
widely known as data-dependent analysis. [Note: “Data-dependent” analysis is often associated
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with the Intelligent Data-Dependent tools of Thermo Finnigan instruments. This term is
analogous to SmartSelect (Bruker Daltonics, Inc.) and Information Dependent Acquisition
(Applied Biosystems).] This feature enables the instrument to make real-time decisions
concerning the experiment at hand. For example, as peptides are eluted from an HPLC
separation, the mass spectrometer continuously acquires full scan data. Once an ion is detected
above a preset threshold, the instrument automatically switches from full scan to MS/MS mode
to perform a tandem experiment on that ion. In the event of multiple, coeluting peptides, the
instrument will perform a MS/MS analysis on one ion (usually the most intense), place that ion
on an exlusion list, and then continue on with its data-dependent analysis of other ions present in
the full scan. Once an ion is subjected to MS/MS and placed on the exclusion list, it remains
there and will not be polled again for a user-defined length of time. The time required for the
mass spectrometer to perform a cycle of one analytical full scan followed by one analytical
MS/MS scan is dictated by the duty cycle of the instrument. For ion trap instruments, one
analytical scan can be composed of a number of averaged scans. Averaging multiple scans to
build one analytical scan is necessary to improve the ion statistics achieved by the ion trap mass
analyzer. However, increasing the number of averaged scans reduces the duty cycle of the
instrument, thus reducing the frequency of acquiring analytical scans. This, in turn, results in
fewer MS/MS experiments that can be conducted over a given period of time. In cases where
poor chromatographic resolution generates several overlapping peptides, fewer analytical scans
per unit time may prevent some peptides from being subjected to an MS/MS experiment. The
frequency of analytical scan acquisition is influenced by instrumental parameters such as the
number of averaged full scans, the number of averaged MS/MS scans, and ion trap injection
time.
In our laboratory, we utilize a micro-flow liquid chromatographic (micro-LC) system for
the proteomic analysis of digested protein mixtures. In this setup, we utilize 320 µm I.D.
capillary columns and flow rates on the order of 4 µL/min. This arrangement provides us with
the reliability we need to analyze large volumes of samples of unknown quality and/or origin.
Although micro-LC may be slightly less sensitive, its robustness far surpasses that of nano-flow
(200-300 nL/min) systems. Nano-LC setups are commonly subject to plugging due to their
small column and emitter inner-diameters, making the analysis of “real world” samples a
challenge. Additionally, when dealing with nL/min flow rates, dead volumes become a greater
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concern. This issue is typically dealt with by using trapping columns. By first loading the
sample onto a trapping column at higher flow rates (i.e.; µL/min regime), then switching to
nano-flow for the analytical separation, long sample loop evacuation times are avoided. This,
however, normally requires multiple LC pumps and valving/switching capabilities.
To perform successful bottom-up proteomics, a delicate balance between peak capacity,
analytical scan acquisition rate, and ion abundances must be achieved. Ion abundance is largely
dictated by the amount of protein present in the sample. In most “real world” samples, it is
impossible to optimize the quantities of all proteins present. Therefore, the majority of effort
must be spent optimizing peak capacity and the analytical scan acquisition rate. As mentioned
previously, great advancements in increasing peak capacity have been made with the
development of multidimensional techniques. Now we have the capability to resolve orders of
magnitude more peptides than was possible with traditional one-dimensional LC techniques. A
large number of laboratories are currently using quadrupole ion traps for proteomics research.
Recently, the Proteomics Research Group (PRG) of the Association of Biomolecular Research
Facilities (ABRF) conducted an open study in which research laboratories were invited to
participate (126). The study required the participants to identify the sequences and
phosphorylation sites of a peptide mixture. A total of 57 different laboratories participated in
this study. Of these, 39% of the laboratories utilized ion trap mass analyzers, attesting to the
utility of ion traps in proteomics. However, to date, very little consideration has been given to
the optimization of ion trap parameters for proteomics applications. Parameters such as the
number of averaged scans (full scan and MS/MS) and the injection time for ion accumulation
play a critical role in achieving high quality spectra. Simultaneous optimization of all three
elements is crucial to achieve high quality MS/MS spectra of all peptides present in a sample.
This, in turn, will result in more accurate fragment ion assignments by database searching
algorithms leading to higher protein correlations.
In this work, we investigate the scan parameters of one variety of ion trap mass analyzer,
the LCQ Deca. Furthermore, we report the effects of these parameters on the data-dependent
algorithm and our ability to analyze the maximum number of closely eluting peptides. The
balance between ion trap scan parameters and the ability to maintain an analytical scan
acquisition rate amenable to interrogating the maximum number of peptides are explored. We
present these experimental parameters and their influence on the quality of MS/MS data.
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EXPERIMENTAL
Materials

Bovine serum albumin (BSA), ammonium acetate (NH4HCO3), and ammonium
bicarbonate were obtained from Sigma Chemical Co. (St. Louis, MO). HPLC grade water,
HPLC grade acetoniltrile (I), and formic acid were purchased from Fisher Scientific (Fair Lawn,
NJ). Sequencing grade modified trypsin was a product of Promega (Madison, WI).

Digestion of BSA

A stock solution of 2 µg/µL BSA was prepared in 50 mM NH4HCO3. A 50 µL aliquot
was removed and mixed with 50 µL of I to improve proteolysis (127). Trypsin was added to a
final protease-to-BSA ratio of 1:40, and the digestion mixture was incubated at 37 °C for 24 h.
The resulting digested BSA sample was used to prepare 10-, 100-, and 1000-fold serial dilutions
in water (i.e.; protein concentrations of 100, 10, and 1 ng/µL, respectively).
Chromatography and Mass Spectrometry

Digested BSA samples were resolved on a 15 cm x 320 µm I.D. reverse phase capillary
column. This column was fabricated in-house and packed with 5 µm Macrosphere 300 C18
particles (Alltech Associates, Inc., Deerfield, IL) using a stainless steel packing cell pressurized
with helium to 1000 psi . Sample introduction and mobile phase delivery at 4 µL/min was
performed by a LC Packings Ultimate capillary LC system (San Francisco, CA) equipped with a
5-µL injection loop. Mobile phase A was water + 0.1% formic acid and mobile phase B was I +
0.1% formic acid. A linear gradient of 5-95 % B over 55 min was employed for the separation
of the BSA peptides.
Eluting peptides in the column effluent were directly electrosprayed into a Finnigan LCQ
Deca ion trap mass spectrometer (Thermo Finnigan, San Jose, CA) for analysis. The
electrospray source was given 4.5 kV of applied voltage and 33 arbitrary units (range 0-100) of
sheath gas flow, while the inlet capillary was held at 19.5 V and 170 °C. Other mass
spectrometer parameters were as follows: tube lens offset at –15.0 V, multipole 1 offset at –5.3
V, multipole 2 offset at –11.0 V, intermultipole lens at –77.0 V, entrance lens at –82.0 V and trap
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DC offset at –10.0 V. Spectra of eluting BSA peptides were acquired in a data-dependent
fashion by first acquiring a full MS scan from m/z 150 to 2000 followed by a MS/MS scan
between m/z 150 and 2000 of the most intense ion of the previous full MS scan. MS/MS scans
were acquired using an activation qz of 0.250, activation time of 30 ms, and 35% normalized
collision energy (NCE). (Note: NCE, is the amplitude of the resonance excitation RF voltage
scaled to the precursor mass based on the formula: RF amplitude = [NCE% / 30%] (precursor ion
mass × tick amp slope + tick amp intercept), where the tick amp slope and tick amp intercept are
instrument specific values. For our LCQ Deca, 35% NCE for m/z 1000 = 1.8 V.) Once sampled,
each MS/MS precursor mass was excluded from further tandem experiments for three minutes.
For each analytical full MS and MS/MS scan, m number of MS scans and n number of MS/MS
scans were averaged, respectively. In these experiments, 5-µL injections of the 10-fold dilution
(100 ng/µL) of digested BSA were analyzed 25 times; each time m and n were assigned a value
of 1, 3, 5, 7, or 9 averaged scans until a five-by-five experimental array had been acquired. To
further refine the impact of sample concentration on the quality of MS/MS scans, similar
experiments were performed on the 100-fold (10 ng/µL) and 1000-fold (1 ng/µL) dilutions of
digested BSA; however, in these cases, only 1, 5, and 9 MS and MS/MS averaged scans were
investigated to produce a three-by-three array of data.
A flow injection experiment was also performed in which the reverse phase capillary
column was removed and replaced with 50 µm I.D. PEEK tubing. Mobile phase (5% I) was
delivered at 4 µL/min to the electrospray source of the mass spectrometer as before. BSA digest
(10 ng/µL) was introduced into the flow in 5-µL injections. As the sample plug was sprayed into
the mass spectrometer, spectra were again collected in a data-dependent manner for a time period
of one minute. For this experiment, injections were repeated in triplicate for n = 1, 3, 5, 7, and 9
averaged MS/MS scans, while the number of averaged full scans was held constant at m = 3. In
all experiments, the automatic gain control (AGC) of the instrument was turned on with target
values of 5.0 x 107 and 2.0 x 107 for the MS and MS/MS scans, respectively. For the 10-fold
dilution studies, the maximum ion injection times were set at 300 ms for the full scans and 500
ms for the MS/MS scans. For all other experiments, the maximum MS/MS ion injection time
was increased to 600 ms.
To evaluate the quality of data acquired, the MS/MS spectra were searched against the
NCBI non-redundant database using the SEQUEST algorithm to generate cross-correlation
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scores for each peptide. However, in each experiment, attention was only given to the spectra
acquired within a five-minute window (approximately t = 21.5 – 26.5 min) where several
peptides were coeluting. The resulting cross-correlation scores (Xcorrs) were subjected to
criteria as set by Washburn, et al. (68). In short, +1, +2, and +3 charged peptides had to be
tryptic in nature and have cross-correlation scores of at least 1.8, 2.2, and 3.75, respectively.
BSA peptide correlations not meeting these criteria were considered to have ambiguous
identifications.
RESULTS AND DISCUSSION

In these experiments, we explored various ion trap parameters (i.e., number of averaged
full scans, number of averaged MS/MS scans, and ion injection times) capable of sampling as
many poorly resolved peptides as possible, while maintaining high quality MS/MS spectra. A
typical reverse phase separation of tryptic BSA peptides is shown in Figure 3.1. The shaded area
denotes the five-minute time window that was considered for this study. In this window, several
peptides coeluted with overlapping peaks. We focused only on these peptides because we
wished to mimic very complex mixtures of peptides and to tax the instrument’s data-dependent
function.
Analysis of the 10-fold diluted BSA digest at the various numbers of averaged scans (m
and n = 1, 3, 5, 7, and 9) yielded a five-by-five matrix of 25 total runs. To understand the effect
that the number of averaged scans had on the instrument’s frequency of acquiring analytical
scans, we looked at the number of MS/MS spectra acquired during the five-minute window of
interest for each run (Table 3.1). The number of MS/MS spectra varied from as many as 139 (m
= 1 full scan, n = 1 MS/MS scan) to as few as 26 (m = 9 full scans, n = 9 MS/MS scans). Further
investigation showed that the average instrumental processing time required to acquire one
analytical full scan followed by one analytical MS/MS scan ranged from 1.9 s (m = 1 full scan, n
= 1 MS/MS scan) to 15.4 s (m = 9 full scans, n = 9 MS/MS scans). This illustrated how the
frequency of acquiring analytical scans affected the number spectra that could be acquired over a
given time. As the total number of averaged scans that had to be acquired and averaged was
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Figure 3.1. A chromatogram depicting a typical reverse phase separation of BSA tryptic
peptides. The shaded region represents the five-minute window of interest and contains several
poorly resolved, coeluting peptides. In all experiments, only peptides eluting in this region were
evaluated.
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Table 3.1. Number of MS/MS spectra acquired at various combinations of averaged full scans
and MS/MS scans.

Number of Averaged Full Scans

Number of Averaged MS/MS Scans
1

3

5

7

9

1

139

81

60

46

38

3

100

67

51

42

34

5

73

57

46

36

30

7

62

49

39

33

27

9

54

40

34

30

26
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increased, more time was required to generate one analytical scan, which in turn resulted in a
fewer number MS/MS spectra that could be obtained. For this reason, fewer number analytical
scans per second would be undesirable in situations where several peptides are coeluting.
To better understand the relationship between the number of scans that were averaged
and spectra quality, database searches of the MS/MS spectra acquired during the five-minute
window of interest for all 25 combinations of averaged scans were performed. Only those
spectra yielding unambiguous peptide matches were considered. The numbers of unique BSA
peptides identified for each combination of averaged scans were tabulated (Table 3.2). This set
of experiments yielded as few as 1 and as many as 7 unique peptide matches. However, when
closely examined, the data revealed an area of enriched peptide matches. This area was
bracketed by the ion trap settings of m = 1 full scan, n = 3 MS/MS scans and m = 5 full scans, n
= 9 MS/MS scans. The runs encompassed by these settings produced mostly 5, 6, or 7 BSA
peptide matches. It was also noted that the maximum MS/MS ion injection time of 500 ms was
entirely utilized for almost all of the acquired MS/MS scans.
The amount of injected sample was decreased by a factor of 10 (50 ng on column) in an
attempt to further target a combination of averaged scans that would be superior to the others in
identifying the greatest number of unique peptides. This time, however, the experimental array
was reduced to nine individual runs consisting of combinations of 1, 5, and 9 averaged scans to
expedite the experimental process. In addition, the maximum MS/MS ion injection time was
increased from 500 ms to 600 ms. This resulted in a surprisingly large increase of identified
peptides across the board despite the decrease in sample concentration (Table 3.3). Close
examination of the MS/MS spectra revealed an overall increase in spectral quality, including
increases in total ion intensities and b and y fragment ion coverage. This was especially
pronounced in +3 charged peptides (Figure 3.2). Nonetheless, the previously bracketed
combinations of averaged scans (m = 1 full scan, n = 3 MS/MS to m = 5 full scans, n = 9
MS/MS) seemed to once again generate higher numbers of matched peptides.
To further investigate this, a third array of experiments was conducted using a 1000-fold
dilution of stock BSA digest (5 ng on column; Table 3.4). Again, the array was truncated to a
three-by-three scan matrix using maximum MS/MS ion injection times of 600 ms. Searching
these acquisitions against the database produced matched peptide numbers similar to those
achieved with 500 ng of sample on column with maximum MS/MS injection times of 500 ms.

57

Table 3.2. Number of unique peptides unambiguously identified from 500 ng of BSA digest at
various combinations of averaged full scans and MS/MS scans.

Number of Averaged Full Scans

Number of Averaged MS/MS Scans
1

3

5

7

9

1

3

6

5

4

4

3

3

6

5

5

5

5

4

3

7

5

5

7

1

2

5

4

3

9

4

4

3

5

3
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Table 3.3. Number of unique peptides identified from 50 ng of BSA digest at various
combinations of averaged full scans and MS/MS scans.

Full Scans

Number of Averaged

Number of Averaged
MS/MS Scans
1
5
9
1

8

10

8

5

8

8

10

9

7

7

7
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Figure 3.2. MS/MS spectra of BSA peptide KVPQVSTPTLVEVSR (+3) at 547.7 m/z. (a) 500
ng of BSA digest with a maximum ion injection time of 500 ms. (b) 50 ng of BSA digest with a
maximum ion injection time of 600 ms.
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Table 3.4. Number of unique peptides identified from 5 ng of BSA digest at various
combinations of averaged full scans and MS/MS scans.

Full Scans

Number of Averaged

Number of Averaged
MS/MS Scans
1
5
9
1

3

4

5

5

2

4

4

9

3

3

3
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Once again, an area of enhanced peptide correlation was observed in the upper right hand
quadrant of the table as bracketed by m = 1 full scan, n = 3 MS/MS scans and m = 5 full scans, n
= 9 MS/MS scans.
The impact that the ion injection times had on the number of identified BSA peptides was
quite remarkable and warranted further investigation. To do this, we held the combination of
averaged full scans and MS/MS scans at 3 and 5, respectively. Triplicate analyses of the 1000fold dilution of BSA digest were performed at maximum ion injection times of 500, 600, and 700
ms. To evaluate the effect that injection times had on the quality of acquired MS/MS spectra, we
looked at the average Xcorr of four unique BSA peptides (Table 3.5). In all cases, the MS/MS
spectra acquired with 600-ms maximum injection times provided correctly assigned peptide
sequences and yielded the best Xcorrs. Acquisitions at 500 and 700-ms maximum injection
times, however, produced statistically lower Xcorrs and occasionally generated SEQUEST
search results that were not the proper amino acid sequences for these peptides. Examples of
MS/MS spectra acquired at each ion injection time for the BSA peptide HLVDEPQNILK are
shown in Figure 3.3. These results indicated that a maximum ion injection time of 500 ms was
not sufficiently long enough to fill the ion trap with a suitable population of precursor ions. In
this case, few fragment ions were generated, contributing to low total ion current, thus leading to
poor MS/MS spectra quality. On the other hand, 700 ms may have been too long to accumulate
ions in the trap, resulting in space charge effects. It should be noted that, in most MS/MS scans,
all 700 ms were utilized for ion accumulation, which may have been an indication that the AGC
target value of 2.0 x 107 was too high.
A flow injection experiment was performed in an attempt to further isolate an ideal set of
scan parameters. Sample introduction of 10 ng/µL BSA digest was made in multiple 5-µL
injections. As each sample plug was sprayed into the mass spectrometer, the instrument acquired
as many data-dependent spectra as possible in one minute, the elution time of a typical
chromatographic peak (i.e.; full width at base). For each injection, the number of full scans was
held constant at m = 3, while the number of averaged MS/MS scans was set at n = 1, 3, 5, 7, or 9.
Once again, this experiment illustrated the impact that the number of averaged scans had on the
frequency of acquiring analytical MS/MS spectra. The combination of m = 3 full scans and n = 1
MS/MS scan produced an average of 24.7 ± 0.6 analytical MS/MS scan attempts during the oneminute time period, while n = 9 MS/MS scans yielded only 9.3 ± 0.6 attempted analytical
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Table 3.5. Average cross-correlation scores of four unique BSA peptides using 500, 600, and
700-ms MS/MS maximum ion injection times.

AEFVEVTK (+1)

LVTDLTK (+1)

500 ms

1.87 ± 0.06†

1.52 ± 0.18†

600 ms

2.18 ± 0.19

†

†

700 ms

1.53 ± 0.34†

1.67 ± 0.10
N/A*

*N/A = peptide was not correctly identified in all replicates.
†
Relative standard deviation.
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HLVDEPQNLIK (+2)

KVPVQVSTPT
LVEVSR (+2)

N/A*

N/A*
†

3.70 ± 0.49†

2.80 ± 0.09†

2.97 ± 0.46†

3.37 ± 0.24

TIC = 6.1 x 103
Xcorr = N/A*
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Figure 3.3. SEQUEST b and y ion assignments for MS/MS spectra of BSA peptide
HLVDEPQNLIK (+2) . (a) Spectrum acquired with 500-ms maximum ion injection time. (b)
Spectrum acquired with 600-ms maximum ion injection time. (c) Spectrum acquired with 700ms maximum ion injection time. *N/A = amino acid sequence incorrectly identified.
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MS/MS spectra. The quality of these spectra was exhibited in the number of BSA peptides that
were identified during the one-minute acquisition time. On average, only 1.0 ± 0.0 BSA peptide
was identified with m = 3 full scans and n = 1 MS/MS scan, whereas 3.3 ± 0.6 peptides were
identified using n = 9 MS/MS scans. Once again, this demonstrated how the ion statistics were
improved by averaging more scans, leading to higher quality spectra. Closer inspection of the
data showed that 1 and 3 averaged MS/MS scans produced insufficient spectra quality and led to
the identification of ≤ 1 BSA peptide on average. The greatest enhancement in spectra quality
was achieved by increasing the number of averaged MS/MS scans from 3 to 5, with more subtle
increases in quality from 5 to 7 and 7 to 9 averaged MS/MS scans. However, by plotting the
number of attempted analytical MS/MS spectra and the number of identified BSA peptides both
as a function of averaged MS/MS scans on the same graph (Figure 3.4), the inverse relationship
between the number of acquired MS/MS spectra and spectrum quality became apparent.
Although 9 averaged MS/MS scans yielded the greatest number of identified peptides, the time
required to assemble one analytical MS/MS spectrum was too long for a typical proteomics
analysis of a complex mixture of peptides and would result in missing some coeluting peptides.
It became evident that a compromise must be made between the frequency of acquiring
analytical MS/MS scans and spectrum quality. The combination of m = 3 full scans and n = 5
MS/MS scans seemed to be the logical choice. The 5 averaged MS/MS scans produced spectra
that were far superior to that of 1 or 3 averaged MS/MS scans while requiring less acquisition
time than 9 averaged MS/MS scans. One may argue that 7 averaged MS/MS scans are even
better than 5, but upon inspection of the their respective number of BSA peptides that were
cumulatively identified from the three replicate flow injection runs, only one more peptide was
identified using 7 averaged MS/MS scans than was identified using 5 averaged scans. In light of
the need for high spectrum acquisition frequency, this was not a significant enhancement.
These experiments revealed the complexity of optimizing ion trap parameters for the
purpose of performing bottom-up proteomics in a data-dependent fashion. It was obvious that
one element to achieving high quality MS/MS spectra was the ion abundance in the trap
demonstrated by the ion injection time experiments. Adding to this complexity was the dynamic
ion abundance across an eluting peptide peak. The location on the peak at which an MS/MS was
performed greatly affected the quality of the MS/MS spectrum and the resulting Xcorr
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Figure 3.4. A graph depicting the results of the flow injection experiment using 5 µL injections
of 10 ng/µL BSA digest. Spectra were acquired in a data-dependent manner for one minute.
The graph shows the number of analytical MS/MS spectra that were attempted (#) and the
number of identified BSA peptides (!) as a function of the number of averaged MS/MS scans.
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(Figure 3.5). Ideally, it would have been desirable to acquire an MS/MS spectrum of an eluting
peptide at the apex of its chromatographic peak since this would provide the highest abundance
of precursor ions in the trap, thus the highest possible quality of spectrum. Unfortunately, there
is currently no way to accomplish this feat.
CONCLUSIONS

In this chapter, we describe a range of ion trap parameters for the Finnigan LCQ Deca ion
trap mass spectrometer to enhance the ability to acquire high quality MS/MS spectra for the
purpose of proteomics. We have illustrated how achieving high quality spectra requires the
simultaneous cooperation of several dynamic elements, including peak capacity, analytical scan
acquisition rate, and ion abundance. For example, we have shown how decreasing the number of
analytical scans per second by averaging more scans reduces the number of spectra that can be
acquired over a given time. However, to achieve high quality spectra amenable to unambiguous
peptide correlations, we must average at least m = 1 full scan and n = 3 MS/MS scans. On the
other hand, when dealing with very complex mixtures of peptides that may generate poorly
resolved or coeluting chromatographic peaks, we have determined that no more than 5 full scans
and 9 MS/MS scans should be averaged. Beyond this, spectrum quality is not necessarily
increased, but rather the rate of acquiring analytical scans becomes too slow and some eluting
peptides are not polled. We have also shown that by changing the maximum ion injection time
from 500 ms to 600 ms, the quality of MS/MS spectra is greatly increased, leading to better
peptide correlations.
In conclusion, we have determined that to identify a unique set of ion trap parameters
applicable to proteomics LC/MS/MS experiments, a compromise must be made between the
acquisition frequency of analytical scans and the resulting quality of the MS/MS spectra. For
most data-dependent proteomics experiments, we have shown that the following rule of thumb
would apply: 3 averaged full scans, 5 averaged MS/MS scans, and a maximum ion injection time
of 600 ms. These settings produce MS/MS spectra among the highest possible quality while still
maintaining a rate of spectrum acquisition that is capable of analyzing all eluting peptides in a
complex mixture.
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Figure 3.5. Cross-correlation scores for BSA peptide KVPQVSTPTLVEVSR (+2), 880.8 m/z.
MS/MS spectra were obtained at the denoted locations on the chromatographic peak and
subjected to a protein database search with SEQUEST.
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CHAPTER FOUR
PROTEOMIC ANALYSIS OF HUMAN VENTRICULAR CEREBROSPINAL FLUID
FROM NEUROLOGICALLY NORMAL, ELDERLY SUBJECTS USING TWODIMENSIONAL LC-MS/MS
INTRODUCTION

Cerebrospinal fluid (CSF) contains a dynamic, complex mixture of proteins (128-138).
Its direct association with the brain’s extracellular space and free exchange of many biochemical
products with the brain make CSF a valuable reporter of physiological processes occurring in the
central nervous system (CNS). Characterization of the CSF proteome has significant clinical
merit in the identification of biological markers that may be employed in the diagnosis of
neurological disorders (139-148). Alzheimer’s disease (AD) is one such disorder for which a
suitable biomarker has yet to be identified that will accurately reflect brain pathology. AD is the
most common form of dementia marked by progressive neuron loss and cognitive decline.
Currently, definitive diagnosis of AD is made at autopsy where the severity of the disease is
assessed according to the Braak staging model, which evaluates the distribution pattern and
density of neurofibrillary tangles and neuropil threads in the brain (Braak 1-2 = limited AD
pathology, Braak 3-4 = moderate AD pathology, Braak 5-6 = advanced AD pathology) (149151). Recent studies have implicated proteins such as β-amyloid 42 (Aβ42) and protein tau in
CSF as possible indicators for AD (139,152-156) These studies found increased tau and
decreased Aβ42 in AD CSF. Unfortunately, these compounds, at best, are static indicators of
AD and provide little information as to the stage of the disease. Changes in these compounds are
most evident in group comparisons and exhibit extensive overlap between control and AD
individuals. These changes have also been shown to have considerable overlap with those seen
in other neurodegenerative disorders. For these reasons, characterization of the CSF proteome
(control and disease-state) is necessary for the discovery of new biomarkers that may better
reflect the presence and progression of neurological diseases.
In recent years, bottom-up proteomics has gained considerable attention as a popular
approach for proteomics analysis. Bottom-up proteomics begins with enzymatic proteolysis
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(e.g.; trypsin digestion) of a protein or protein mixture. The resulting peptides are separated,
usually by high-performance liquid chromatography (HPLC), and subjected to MS/MS
fragmentation. The MS/MS spectra are subjected to protein database searches using search
algorithms that identify the peptide sequences by comparing the acquired spectra to computerpredicted spectra (91,92). Peptide sequences are correlated to those of proteins within the
database to identify the parent proteins.
When dealing with the large numbers of peptides that are generated from the proteolysis
of complex protein mixtures such as CSF, isolating each peptide for MS/MS analysis can be
extremely challenging. A typical reversed-phase HPLC separation cannot provide adequate
resolution necessary to isolate all peptides generated from such complex protein mixtures. As
such, much attention has recently been directed toward the development of multidimensional
separations for proteomics applications (12,60,61,64,65,68,118,119,122,157,158).
Multidimensional chromatography resolves components in a complex mixture by exploiting
more than one of their chemical/physical characteristics (e.g.; hydrophobicity, charge, and size).
Incorporating a combination of separation modes such as reversed-phase, cation/anion exchange,
and/or size-exclusion into a single chromatographic method, greatly increases the number of
species that can be resolved over a given separation length (i.e.; peak capacity). By coupling
multidimensional chromatographic separations to quadrupole ion trap mass spectrometers, one
gains sufficient chromatographic peak capacity to resolve complex mixtures of peptides/proteins
while performing “on-the-fly” MS/MS analysis. Using protein databases and sophisticated
database searching algorithms, MS/MS spectra can be rapidly correlated to predicted peptide
sequences providing elucidation of protein components within complex mixtures.
In this work, an on-line 2-D LC separation method is described for MS/MS analysis of
human ventricular CSF from 10 cognitively normal, aged subjects. An immuno-based
processing scheme is presented for removal of high concentrations of albumin and Ig to allow for
better detection of lower abundance proteins. Herein, the identification of 249 unique CSF
proteins is reported through the application of these methods and the aid of the SEQUEST
protein database search algorithm. Finally, subject-to-subject variability observed in the CSF
proteome is discussed.
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MATERIALS AND METHODS
Materials

Ammonium acetate, and ammonium bicarbonate (NH4HCO3) were obtained from Sigma
Chemical Co. (St. Louis, MO). HPLC grade water, HPLC grade acetonitrile (I), and formic acid
were purchased from Fisher Scientific (Fair Lawn, NJ). Sequencing grade modified trypsin was
a product of Promega (Madison, WI). Protein A/G Plus-Agarose beads were purchased from
Oncogene Research Products (Boston, MA), and the rabbit anti-human serum albumin antibody
was a product of Research Diagnostics, Inc. (Flanders, NJ). Spin-X centrifuge tube filters
equipped with cellulose acetate membranes having 0.45-µm pores were acquired from Corning
Incorporated Life Sciences (Acton, MA). PrepSep solid-phase extraction (SPE) columns (C18, 1
mL reservoir) were obtained from Fisher Scientific. Flexible fused silica capillary tubing, 320

µm I.D. x 435 µm O.D., used in column fabrication was purchased from Polymicro
Technologies (Phoenix, AZ), while all bulk stationary phase packing material (Macrosphere 300
C18, 5 µm and Partisil SCX, 10 µm) was purchased from Alltech Associates, Inc. (Deerfield,
IL). All other miscellaneous LC accessories, including zero dead volume (ZDV) unions and 2-

µm stainless steel frits, were obtained from Upchurch Scientific (Oak Harbor, WA).
Samples and Sample Preparation

Short post-mortem interval (PMI; mean ± SEM, 2.59 ± 0.21 h) ventricular CSF samples
were obtained at autopsy from 10 (6 males, 4 females) cognitively normal, aged control subjects,
who underwent annual neuropsychological testing as a part of the normal volunteer, longitudinal
aging study at the Sanders-Brown Center on Aging and were without a history of dementia or
other neurological disorders. Neuropathologic evaluation of control brains revealed only ageassociated gross and histopathologic alterations. The mean ± SEM Braak score was 1.7 ± 0.2.
Demographic data for all subjects are shown in Table 4.1. The procedure used to collect the CSF
samples was described previously in an article by Lovell and Markesbery (159)
Sample preparation began with an affinity-based procedure to remove the high
abundance of albumin and Ig. This method was similar to that of Wang et al. described
previously (160). A 150-µL aliquot of Protein A/G Plus-Agarose beads was placed into a SpinX tube and centrifuged at 1000 x g for 1 min to remove the liquid. Beads were washed twice
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Table 4.1. Subject demographic data.

Subject

Sex

Age

PMI (h)a

Braak Score

A

F

92

2.30

2

B

F

92

3.00

2

C

F

72

3.75

1

D

F

85

1.66

2

E

M

86

2.15

2

F

M

79

2.25

2

G

M

77

3.50

1

H

M

87

2.00

2

I

M

87

2.42

2

J

M

2.90
2.59 ± 0.21b

1
1.7 ± 0.2b

84
84 ± 2b
a
Post-mortem Interval. bMean ± SEM
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with 500 µL of PBS. Each wash was followed by centrifugation at 1000 x g for 1 min to remove
the buffer. Rabbit anti-human serum albumin antibody, 100 µL of a 50 µg/µL stock, was added
to the beads in the Spin-X tube along with 200 µL of PBS. Beads and antibody were incubated
at room temperature for 30 min with rocking. The solution was filtered off of the beads with
centrifugation as before, and the beads were washed three more times with 500 µL of PBS. A
250-µL volume of raw CSF was added to the antibody-bound beads in the Spin-X tube. CSF
was incubated with the beads for 30 min at room temperature with rocking. The processed CSF
was collected in a clean 1.5-mL microcentrifuge tube by centrifugation at 2000 x g for 2 min.
The total protein content of the CSF was measured before and after albumin/Ig removal using the
bicinchoninic acid protein assay (BCA).
Following albumin/Ig removal, the CSF was prepared for trypsin digestion. The
collected volume (~250 µL) of processed CSF was evaporated to dryness by vacuum
centrifugation and was reconstituted in 100 µL of 50 mM NH4HCO3 and an equal volume of I to
improve proteolysis (127). Trypsin was added to a final protease-to-protein weight ratio of 1:40,
and the digestion mixture was incubated at 37 °C for 24 h. Following incubation, the mixture
was evaporated to dryness by vacuum centrifugation and resuspended in 200 µL of 5% I/95%
aqueous formic acid (0.1%). The CSF peptides were desalted on a 1-mL SPE column and eluted
with 300 µL of 75% I. Purified CSF peptides were again evaporated to dryness by vacuum
centrifugation. The dried sample was stored at –20 °C until 2-D LC-MS/MS analysis, at which
time it was reconstituted in 20 µL of 5% I containing 0.1% formic acid. The albumin/Ig removal
and digestion procedures described above were repeated for each of the 10 subjects.
Chromatography

Digested CSF samples were resolved on a 18 cm x 320 µm I.D. biphasic capillary
column. This column was constructed with a length of fused silica capillary fitted at one end
with a 2-µm stainless steel frit and a ZDV union. The column was a single-column architecture
comprised of 3 cm of 10-µm Partisil SCX material packed on top of 15 cm of 5-µm Macrosphere
300 C18 particles. The column was packed in-house using a stainless steel packing cell
pressurized with helium to 1000 psi. Sample introduction and mobile phase delivery at 4 µL/min
was performed by an LC Packings Ultimate quaternary capillary LC system (San Francisco, CA)
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equipped with a 20-µL injection loop. Mobile phase A was aqueous formic acid (0.1%), mobile
phase B was I + 0.1% formic acid, mobile phase C was 300 mM ammonium acetate, and mobile
phase D was 5% I + 0.1% formic acid. Each CSF analysis consisted of 13 individual
chromatographic profiles. Profiles 1 to 11 began with a 5-minute (t = 0-5 min) isocratic salt step
consisting of x% C (x = 0, 1.67, 3.33, 5.00, 6.67, 10.00, 13.33, 16.67, 33.33, 50.00, 75.00) and
(100 – x)% D. This was followed by a 2-minute wash (t = 5-7 min) with 95% A and 5% B to
equilibrate the column. Next, a linear gradient was pumped from 95 to 50% A with 5 to 50% B
(t = 7-55 min) followed by a steeper linear gradient from 50 to 20% A with 50 to 80% B (t = 5575 min). The column was returned to initial conditions with a linear gradient from 20 to 95% A
with 80 to 5% B (t = 75-80 min) and equilibrated for 5 minutes (t = 80-95 min) at 95% A and 5%
B before continuing to the next chromatographic profile. Chromatographic profiles 12 and 13
differed only in their initial salt steps. Profile 12 began with 100% C for 15 min, and profile 13
consisted of a manual 20-µL injection of 3 M ammonium acetate prior to the described organic
gradient.
Mass Spectrometry

Eluting peptides in the column effluent were directly electrosprayed into a Finnigan LCQ
Deca ion trap mass spectrometer (Thermo Finnigan, San Jose, CA) for analysis. The
electrospray source parameters were 4.0 kV of applied voltage and 43 units of sheath gas flow,
while the inlet capillary was held at 20.0 V and 170 °C. Other mass spectrometer parameters
were as follows: tube lens offset at –15.0 V, multipole 1 offset at –4.9 V, multipole 2 offset at –
10.0 V, intermultipole lens at –55.0 V, entrance lens at –66.0 V and trap DC offset at –10.0 V.
Spectra of eluting CSF peptides were acquired in a data-dependent fashion by first acquiring a
full scan from m/z 150 to 2000 followed by a MS/MS scan between m/z 150 and 2000 of the
most intense ion of the previous full MS scan (35% normalized collision energy, activation Q of
0.250, activation time of 30.0 ms). Once sampled, each MS/MS precursor mass was excluded
from further tandem experiments for three minutes. To construct each analytical full and
MS/MS scan, 3 full scans and 5 MS/MS scans were averaged, respectively. A maximum ion
trap injection time of 300 ms was used for the full scans and 500 ms was used for MS/MS scans.
The full scan and MS/MS automatic gain control (AGC) target values were set at 5.0 x 107 and
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2.0 x 107, respectively. These settings have been shown to be optimal for proteomics
applications (161).
Protein Identification

Acquired MS/MS spectra were searched against a human protein sub-database extracted
the NCBI non-redundant database using the SEQUEST algorithm (v. 3.0, Thermo Finnigan, San
Jose, CA) (92). SEQUEST results were further filtered using DTAselect (v. 1.9, Yates Lab,
Dept. of Cell Biology, The Scripps Research Institute) (93). Cross-correlation (XCorr) filtering
parameters were set as follows: lowest +1 XCorr at 1.8, lowest +2 XCorr at 2.5, lowest +3
XCorr at 3.5, and the lowest difference between cross-correlation scores (DeltCN) at 0.1.
Protein identification results of individual subjects were compared to one another using Contrast
(v. 1.9, Yates Lab, Dept. of Cell Biology, The Scripps Research Institute) (93).
RESULTS AND DISCUSSION

Identification of proteins in CSF has the potential to serve as a diagnostic tool for a
variety of neurological disorders and may reveal useful neuronal markers that aid in the
diagnosis of such disorders. Recently, there have been several efforts to characterize the CSF
proteome by mass spectrometric techniques (133-138). In most cases, the use of twodimensional gel electrophoresis (2-DE), off-line sample preparation, and/or discontinuous
dimensions of separation modes make these methods extremely time consuming and labor
intensive. Additionally, little consideration has been given to the presence of high abundance
proteins such as albumin and Ig that may mask the low abundance proteins and diminish the
overall sensitivity of a method. Figure 4.1 illustrates the simple affinity-based processing
scheme used in this work to remove albumin and Ig from CSF. Removal of albumin and Ig
eliminated significant contributions of their tryptic peptides to the total ion current of the spectra
and allowed instrumental interrogation of lower abundance peptides. The impact that the
albumin/Ig removal had on the total protein content is demonstrated in Figure 4.2. The protein
concentration of unprocessed ventricular CSF ranged from 0.73 to 1.53 µg/µL (mean ± SEM,
0.88 ± 0.10 µg/µL). Total protein concentration in ventricular CSF has generally been reported
between 0.06 – 0.15 µg/µL, about 1.6 times less than that of lumbar CSF (128). However,
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Anti-Albumin
Antibody
Immunoglobulin
(Ig)

Protein G Plus and
Protein A Conjugated
to Agarose Beads
CSF

Albumin

Elution

Albumin/Ig Depleted
CSF Proteins

Figure 4.1. Depiction of an immuno-based scheme for removal of high abundance albumin and
immunoglobulins (Ig) from human CSF. Albumin is removed via anti-albumin antibody bound
to Protein A/G Plus-Agarose beads, while Ig is captured by unoccupied ProteinA/G Plus sites.
The effluent contains CSF proteins depleted of albumin and Ig.
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Figure 4.2. Protein content in 250 µL of ventricular CSF before (!) and after (") processing to
remove albumin and immunoglobulin (Ig). A mean ± SEM protein recovery of 72.2 ± 0.5% was
achieved.
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protein concentration has been shown to be elevated in elderly subjects (162-164). Regardless of
the starting concentration of protein in unprocessed CSF, post-processing protein quantification
revealed a surprisingly uniform mean ± SEM protein recovery of 72.2 ± 0.5%. In other words,
these results indicated that albumin and Ig accounted for approximately 27.8% of the total
protein in CSF. At first, this percentage seemed slightly low compared to that reported in
literature for ventricular CSF (165). However, if the increase in total protein concentration
exhibited with aging was due to an influx of proteins other than albumin and Ig, it is reasonable
that the relative concentrations of albumin and Ig in CSF would decrease. Increased CSF protein
concentrations of elderly subjects may be a result of changes in the permeability of the bloodbrain/blood-CSF barrier (129).
Two-dimensional LC-MS/MS analysis resulted in 13 individual chromatograms per CSF
sample. With the exception of the first LC separation, each chromatogram consisted of a salt
elution of a peptide fraction from the SCX dimension followed by an organic gradient to resolve
the peptides on the C18 phase. This greatly increased the peak capacity of the system by
fractionating CSF peptides over 13 reversed-phase separations compared to the single organic
gradient of a typical one-dimensional chromatographic method. For example, Figure 4.3 shows
11 tryptic peptides of apolipoprotein E (apoE) were fractionated over 6 individual
chromatograms. (Apo E mediates binding, internalization, and catabolism of lipids. The apoE4
isoform has been linked to sporadic AD.) The bottom panel shows a typical data-dependent
MS/MS spectrum of one of these peptides. By searching this spectrum against the human
protein database with SEQUEST and filtering the results with DTAselect, this peptide was
identified as apoE peptide LSKELQAAQAR with a high degree of confidence (XCorr = 3.39).
All eluting peptides were subjected to data-dependent MS/MS, and the resulting spectra were
analyzed in this manner. SEQUEST search results from all 10 subjects were collectively filtered
with DTAselect using the parameters listed in Table 4.2. Filters not listed in this table remained
at their default settings. As such, we were able to cumulatively identify 249 unique proteins
from 727 non-redundant peptides. Of these proteins, 55% were based on the identification of a
single, unique peptide. Protein identifications from individual subjects ranged from 53 to 118
proteins (Figure 4.4). Not surprising was the fact that there appeared to be little correlation
between total protein and the number of protein identifications. Often variation in total protein
concentration is not due to changes in the number of unique proteins present in the CSF, but
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15 mM Ammonium Acetate

20 mM Ammonium Acetate

!

30 mM Ammonium Acetate

50 mM Ammonium Acetate

100 mM Ammonium Acetate

150 mM Ammonium Acetate

LSKELQAAQAR
XCorr: 3.39

m/z

Figure 4.3. Six chromatograms containing tryptic peptides of apolipoprotein E (apoE) from a
typical 2-D LC-MS/MS analysis of ventricular CSF. ApoE peptides are illustrated in black. The
bottom panel shows the representative MS/MS spectrum of the peptide denoted with a (!).
From this spectrum, the apoE peptide was identified as LSKELQAAQAR with a crosscorrelation score (XCorr) of 3.39.
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Table 4.2. DTAselect and Contrast Filtering Parameters

Filter Type

Filter Setting

Lowest +1 XCorr
Lowest +2 XCorr
Lowest +3 XCorr
Lowest DeltCN
Lowest charge state
Highest charge state
Duplicate spectra
Include only loci with uniquely
matching peptides
Remove proteins that are subsets of others
Show all loci with peptides that appear
Minimum peptides per locus criterion
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1.8
2.5
3.5
0.1
1
3
Purge based on XCorr
False
True
10
1

Number of Proteins Identified

118
108

107

99
89

74

69
56

A

B

95

C

53

D

E

F

G

H

I

J

Subject

Figure 4.4. The number of unique proteins identified in the ventricular CSF for each subject.
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rather a result of alterations in the abundance of individual proteins (129). As a further
qualitative assessment of the CSF proteome, each identified protein was categorized by general
function as described in the Swiss-Prot protein database (Swiss Institute of Bioinformatics,
Basel, Switzerland) (Figure 4.5). It was not surprising to see that the largest percentage of
identified CSF proteins played a role in physiological signaling processes.
To better understand the variability in CSF protein composition from subject to subject,
the filtered protein identifications from all 10 subjects were compared using the Contrast
computer program. The filtering parameters were kept as described in Table 4.2. The results
revealed a startling variability in the CSF protein composition among subjects (Figure 4.6). Of
the identified proteins, 38% were a contribution of individual subjects. In other words, these
proteins were unique to one subject and were not identified in any of the other nine.
Furthermore, only 6% of the collectively identified proteins were in common with all 10 subjects
in this study. These proteins are listed in Table 4.3. Another interesting observation was the
lack of any trends in the CSF proteome of female subjects versus male subjects. Contrast results
indicated that the CSF proteome was as equally diverse among subjects of the same sex as it was
between subjects of opposite sex. Although variation in the CSF proteome between subjects was
expected, the degree to which it varied was surprising. Many factors may have contributed to
this diversity such as general health status, diet, environment, and pharmaceutical therapies of
the individuals.
In addition to above considerations, the experimental method itself may have introduced
some variability from sample to sample. To better understand the extent to which the
experimental method may have played a role in the observed protein variations among subjects,
we ran one CSF sample in triplicate. Three CSF aliquots from a single subject were processed,
digested, and analyzed as described above. The replicate analyses produced 46, 50, and 53
unique protein identifications after DTAselect filtering of the individual runs. Although the
number of proteins identified from run to run was quite uniform, the proteins themselves did
vary to some extent. We observed that from all three replicates, a collective 73 non-redundant
proteins were identified. Of these, 35% were homologous to all three replicate analyses as
reported by Contrast.
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Figure 4.5. The distribution of all 249 identified ventricular CSF proteins according to their
general function.
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4%

One Subject
38%

All Subjects
6%

Figure 4.6. The percentage of identified ventricular CSF proteins that were homologous among
subjects. An overwhelming 38% of the proteins were unique to individual subjects, while only
6% of all the identified proteins were found in all 10 subjects.
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Table 4.3. Ventricular CSF proteins common to all ten subjects

Ventricular CSF Proteins
Osteopontin
Actin, gamma 1
Macrophage migration inhibitory factor (MIF)
Secretory granule, neuroendocrine protein 1 (7B2 protein)
Cystatin C
Alpha 1-antitrypsin
Neuro-endocrine specific protein VGF
Apolipoprotein E
Dopamine- and cAMP-regulated neuronal phosphoprotein 32
Aldolase A
Beta-trace
Enolase 1
Phosphoglycerate mutase 1
Prostaglandin D2 synthase
Superoxide dismutase 3, extracellular
Granin-like neuroendocrine peptide precursor, proSAAS
Cyclophilin A
Glyceraldehyde-3-phosphate dehydrogenase
Hemoglobin
Transthyretin
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Investigation of the data from the triplicate runs revealed insight to the variability
observed in the replicate analyses. It was observed that 67% of the total identified proteins were
based on the identification of a single, unique peptide. The reason for such a large percentage of
single-peptide identifications was unclear, but may have been a result of incomplete trypsin
digestion or due to the sheer complexity of the peptide mixtures at hand. Nonetheless, one could
envision that proteins whose identities rely on the analysis and identification of single peptides
would have a lower probability of being observed in replicate runs compared to those proteins
that can depend on multiple peptides for identity. In other words, a protein relying on a single
peptide for identification only gets one shot to be observed. If the peptide is not identified as a
result of a poor quality MS/MS spectrum, being missed in a coelution of several peptides, or
simply being below the limit of detection, the associated protein will not be accounted for. This
would produce variations in protein identifications in replicate analysis.
Further examination of the data revealed that these types of scenarios do in fact occur.
Figure 4.7 illustrates a case in which a peptide of haptoglobin (RILGGHLDAKGSFPWQAKM,
m/z = 913.1, +2) was present and subjected to MS/MS in all three replicate analyses of CSF.
(Haptoglobin is responsible for binding free hemoglobin, thus preventing the loss of iron. In its
non-neuronal role, it protects the kidneys from renal damage.) In two of the three runs, the
MS/MS spectrum of the peptide was of sufficient quality (XCorr > 2.5) to produce a proper
identification. However, in the third replicate, the MS/MS spectrum yielded an XCorr of 2.04, a
score too low to produce an unambiguous identification of the peptide. As a result, DTAselect
filtered out the peptide, and haptoglobin was not identified in that replicate.
Figure 4.8 represents an example of a peptide that was analyzed and identified in two of
the replicates but missed being subjected to an MS/MS experiment in the third replicate due to
coelution with other peptides. Figures 4.8a and 4.8b show, from separate replicates, the
extracted ion chromatograms and MS/MS spectra of a peptide from complement component 3
(C3) protein, a multifunctional protein that plays the central role in the activation and regulation
of the complement system. These spectra led to the proper identification of the peptide sequence
RTKKQELSEAEQATRT in these two replicates. However, in the third replicate this peptide
coeleuted with four other peptides causing it to be missed by the data-dependent MS/MS analysis
(Figure 8c). Although m/z 810.2 was not subjected to MS/MS in the third replicate, we can
assume with a high degree of certainty that this ion is the same peptide because it eluted during
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Figure 4.7. MS/MS spectra of haptoglobin peptide RILGGHLDAKGSFPWQAKM (m/z =
913.1, +2) from replicate analyses of one CSF sample. SEQUEST database searches of spectra
(a) and (b) yielded sufficient XCorr scores (>2.5) to unambiguously identify the peptide.
Spectrum (c) generated an inadequate XCorr score (<2.5) which could not unambiguously
identify the peptide and, therefore, did not identify haptoglobin in that replicate.
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Figure 4.8. Chromatographic and mass spectral data of complement C3 peptide
RTKKQELSEAEQATRT (m/z = 810.2, +2) from triplicate analyses of one CSF sample. Panels
(a) and (b) show extracted ion chromatograms and MS/MS spectra for the peptide in two
replicates. A full scan spectrum (c) from the third replicate shows of the precursor ion coeluting
with other ions. The peptide was “overlooked” by the data-dependent algorithm of the
instrument and not subjected to MS/MS. As a result, complement C3 was not identified in the
third replicate analysis.
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Figure 4.8 (continued). Chromatographic and mass spectral data of complement C3 peptide
RTKKQELSEAEQATRT (m/z = 810.2, +2) from triplicate analyses of one CSF sample. Panels
(a) and (b) show extracted ion chromatograms and MS/MS spectra for the peptide in two
replicates. A full scan spectrum (c) from the third replicate shows of the precursor ion coeluting
with other ions. The peptide was “overlooked” by the data-dependent algorithm of the
instrument and not subjected to MS/MS. As a result, complement C3 was not identified in the
third replicate analysis.
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the same chromatographic profile (number 10) and with approximately the same retention time.
As a result, the complement C3 protein was not identified in this replicate. This example
illustrates a source of variability attributed to the nature of the data-dependent acquisition of the
mass spectrometer in combination with the shear complexity of the peptide mixtures. For
example, at a given point in time during the organic gradient of two identical 2-D LC
separations, it may be impossible to have the identical relative abundances and resolution of
peptides eluting from the column. These changes in relative abundances and resolution of
peptides result from the extreme complexity of the peptide mixtures and slight variations in
chromatography of the SCX and/or C18 phases. Adding to this dynamic is the data-dependent
manner in which the instrument conducts an MS/MS experiment. Repetitive cycling of
precursor ion selection and subsequent MS/MS analysis of dynamically changing peptide signals
can easily lead to omission of individual peptides from sampling during a complex 2-D
separation.
Finally, we observed cases in which peptides were not identified in replicate runs because
the peptide was simply absent or present below the limit of detection. Carbonic anhydrase,
whose basic physiological function is the interconversion between carbon dioxide and
bicarbonate, was one example for which we observed and identified a tryptic peptide
(KAVQQPDGLAVLGIFLKV) in only one of the replicate analyses (data not shown).
Inspection of the data from the other two replicates revealed that this peptide was either not
present or below the detection limit of the instrument. In this case, carbonic anhydrase was
identified in only one of the three replicate experiments.
CONCLUSIONS

We have used 2-D LC-MS/MS technology to characterize the ventricular CSF proteome
of 10 cognitively normal, elderly subjects. With the aid of an affinity-based processing scheme
to remove high concentrations of albumin and Ig, we were able to analyze lesser abundant
proteins. Protein assays before and after processing indicated that, albumin and Ig consistuted
approximately 27.8% of the total protein in ventricular CSF of these aged subjects. Using
protein database search and filtering algorithms, we have identified a collective 249 unique
proteins. Of these proteins, only 6% were identified in all 10 subjects, while 38% remained
unique to individual subjects. These results appear to indicate a large diversity in the CSF
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proteome among individuals. However, we have also identified a source of viability in the 2-D
LC-MS/MS method itself when dealing with very complex mixtures of peptides, despite the
considerable gains in peak capacity and resolving power. Regardless, we have demonstrated 2-D
LC-MS/MS as a viable method for rapid identification of CSF proteins.
SUPPLEMENTAL DATA

A complete list containing all 249 unique CSF proteins and associated peptides cumulatively
identified from 10 neurologically normal, elderly subjects is provided in Appendix A.
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CHAPTER FIVE
QUANTITATIVE PROTEOMICS ANALYSIS OF VENTRICULAR CEREBROSPINAL
FLUID FROM CONTROL AND ALZHEIMER’S DISEASED SUBJECTS
USING 2-D LC-MS/MS
INTRODUCTION

As discussed previously, the new discipline of proteomics is concerned with the largescale analysis of protein properties, including identity, chemical character, and abundance (10).
Such information provides valuable insight for elucidating physiological processes that occur
during normal and disease states at the cellular level. The previous chapter provided a
qualitative examination of the ventricular CSF proteome of neurologically normal, aged subjects.
As such, only the identification of CSF proteins was addressed. In this chapter, a quantitative
proteomics approach is described. Through the use stable isotope labeling coupled with 2-D LCMS/MS, a quantitative comparison of control and Alzheimer’s disease ventricular CSF is
presented.
Since the conception of proteomics less than a decade ago, a variety of methods have
been utilized in attempts to quantify levels of expressed proteins (166-169). One method that has
received considerable attention is that of DNA microarrays (18,170). This approach makes use
of immobilized cDNA or short oligonucleotides to probe mRNA transcribed from genes. It is
then assumed that the abundance of mRNA is indicative of protein expression level for a
particular gene. Unfortunately, mRNA itself is subject to secondary processing and regulation,
resulting in discrepancies between mRNA and protein levels as has been shown in recent studies
(19,171,172).
“Classical proteomics” has typically employed two-dimensional polyacrylamide gel
electrophoresis (2D-PAGE) for resolving complex protein extracts (173,174). The resulting
protein maps are often used as a comparative view of protein abundances between reference and
altered cell or tissue states. In this approach, proteins from normal and altered states are resolved
on separate gels, stained, and then imaged. Intensities of protein spots from each gel are
compared to determine relative expression ratios between the two states. Unfortunately, this
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method suffers from several drawbacks. The process of casting gels, running 2D-PAGE,
staining, and imaging can be very time consuming and labor intensive. Once the gel is imaged,
spot recognition and quantification of hundreds of proteins on one gel can also be a very
overwhelming task, even with the aid of modern computer programs. Additionally, running
reproducible two-dimensional gels can be very difficult. When comparing protein intensities
between two gels, it is very important that protein migration on each gel be nearly identical, such
that spots from each gel can be recognized as the same protein based upon their locations on the
gels.
Recently, the development of differential in-gel electrophoresis (DIGE) has eliminated
the need to reproducibly run two separate gels (175). Rather, the control and reference protein
extracts are labeled with two different colors of fluorescent dyes, mixed, and run together on one
two-dimensional gel. Relative protein levels are obtained from the relative intensities of the two
fluorescent colors present in each protein spot. Unfortunately, this system is susceptible to
misleading quantitation when proteins are not well resolved and more than one protein is present
in a single spot.
To deal with the problems associated with quantitation using 2D-PAGE, many research
groups have turned to mass spectrometry and stable isotope labeling (166-169,176). In this
approach, a stable isotope (e.g., 2H, 13C, 15N) is incorporated into the proteins from one of the
tissue/cell states (control or altered) to be analyzed. These “heavy” labeled proteins are then
mixed with the “light” proteins from the second state, digested with trypsin, and subjected to
mass spectral analysis. The relative ratio of light vs. heavy ion intensities is indicative of the
relative protein abundances present in the original samples. In this manner, the stable isotopelabeled peptides become internal standards, differing only in mass from their light counterparts,
but not in chemical composition. Light and heavy components of an isotope pair, in theory,
should have identical physico-chemical properties, causing them to behave the same under any
given separation or ionization procedure. As such, relative intensities of isotope pairs accurately
reflect relative peptide ratios.
A variety of quantitative proteomic methods using stable isotope labeling have been
described in literature. These methods can be grouped into one of three general categories: in

vivo labeling (117,177-179), pre-digestion in vitro labeling (180-186), and post-digestion in vitro
labeling (187-191). The general schemes of these methods are illustrated in Figure 5.1. In vivo
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Figure 5.1. Three general schemes for using stable isostope labels in quantitative proteomics.
They include: (a) in vivo labeling, (b) pre-digestion in vitro labeling, and (c) post-digestion in

vitro labeling.
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labeling utilizes heavy media on which cells of a particular state are grown, while cells of a
different state are grown on media lacking heavy isotopes. As cells grow on the heavy media,
stable isotopes are incorporated into the translated proteins. Both populations of cells are then
mixed together, proteins extracted, and digested with trypsin prior to MS analysis. Pre- and postdigestion in vitro labeling, on the other hand, directly label the protein extract with the stable
isotope. The only difference between these two techniques is when the extract is labeled in
relation to the trypsin digestion. Post-digestion in vitro labeling is typically used to add heavy
and light modifications to carboxyl or amino groups following trypsin digestion, whereas predigestion in vitro labeling is used to add stable isotope labels to the thiol group of cysteine
residues prior to trypsin digestion.
Recently, Aebersold and coworkers developed an in vitro pre-digestion labeling strategy
that has received considerable attention (180,181,183-186). Called isotope-coded affinity tags
(ICAT), the heavy (d8) or light (d0) reagents used in this method are selectively incorporated
into the proteins extracts through the alkylation of cysteines (Figure 5.2a). The two populations
of proteins are then mixed and digested with trypsin. The novel aspect of ICAT reagents is the
incorporation of a biotin affinity tag that allows for the purification of only ICAT-labeled
cysteine-containing peptides on an avidin column following digestion. This step greatly reduces
the complexity of the sample for MS analysis. However, there are two major disadvantages to
using ICAT reagents. First, the heavy ICAT reagent incorporates eight deuterium atoms to give
an eight-mass unit difference over that of the light reagent (Figure 5.2a). However, when
subjected to chromatographic separations, deuterium labels can significantly alter the retention
characteristics of the peptide (188,192). This may prevent light and heavy peptide pairs from
coeluting, thus making quantitation more difficult. Second, the ICAT modification of ~500 Da,
is a rather large addition to the cysteine residues that is maintained throughout mass spectral
analysis. This can reduce the efficiency of peptide fragmentation. Additionally, fragment ions
from the biotin tag itself can complicate the MS/MS spectrum, making peptide identification
more difficult for protein database searching algorithms (176).
To address these issues, a new generation of ICAT reagents has been developed, called
cleavable ICAT (176,182). To eliminate the deuterium isotope effect, cleavable ICAT reagents
make use of nine 13C atoms to produce heavy labels that are nine mass units heavier than the
light labels. The use of 13C rather than 2H ensures that the chromatographic behavior of isotope
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ICAT reagents (b) utilizes 9 13C atoms to form the heavy label, while incorporating an acidcleavable linker for removing the biotin tag following affinity purification.
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pairs is identical. Furthermore, cleavable ICAT reagents also incorporate an acid-labile linker
between the stable isotope and affinity regions of the label. This provides a means by which
biotin can be cleaved from the tag prior to MS analysis, thus simplifying the MS/MS spectra. A
graphical representation of the cleavable ICAT reagent is shown in Figure 5.2b.
This chapter describes the application of the new cleavable ICAT technology to a
quantitative comparison of control and Alzheimer’s disease ventricular CSF proteomes. As
indicated from the work described in Chapter 4, there is considerable variability in ventricular
CSF protein composition among neurologically normal individuals. These availabilities may
stem from differences in diet, environment, of pharmaceutical influences. Nonetheless, such
protein variability among individual subjects creates difficulties when trying to elucidate
differences between normal and disease-state populations. In this study, a method is described
that utilizes a pool of combined ventricular CSF samples from control (neurologically normal)
subjects. By quantitatively comparing CSF samples from each of nine control subjects and nine
AD subjects to the pool (rather than directly to one another), an attempt is made to normalize
subject-to-subject variability. As before, 2-D LC-MS/MS is used for separation and analysis of
peptides. This time, however, the use of cleavable ICAT reagents provides a means of
quantifying relative abundances of CSF proteins.
EXPERIMENTAL
Materials

HPLC grade water, HPLC grade acetonitrile (ACN), and formic acid were purchased
from Fisher Scientific (Fair Lawn, NJ). Ammonium acetate was obtained from Sigma Chemical
Co. (St. Louis, MO). Sequencing grade modified trypsin was a product of Promega (Madison,
WI). Protein A/G Plus-Agarose beads were purchased from Oncogene Research Products
(Boston, MA), and the rabbit anti-human serum albumin antibody was a product of Research
Diagnostics, Inc. (Flanders, NJ). Spin-X centrifuge tube filters equipped with cellulose acetate
membranes having 0.45-µm pores were acquired from Corning Incorporated Life Sciences
(Acton, MA). Cleavable ICAT 10-Assay Kits were purchased from Applied Biosystems, Inc.
(Foster City, CA) PrepSep solid-phase extraction (SPE) columns (C18, 1 mL reservoir) were
obtained from Fisher Scientific. Flexible fused silica capillary tubing, 320 µm I.D. × 435 µm
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O.D., used in column fabrication was purchased from Polymicro Technologies (Phoenix, AZ),
while PolymerX RP-1, 3 µm and Partisil SCX, 10 µm bulk stationary phase packing material
was purchased from Phenomenex (Torrance, CA) and Alltech Associates, Inc. (Deerfield, IL),
respectively. All other miscellaneous LC accessories, including zero dead volume (ZDV) unions
and 2-µm stainless steel frits, were obtained from Upchurch Scientific (Oak Harbor, WA).
Preparation of CSF Samples and Pool

Ventricular CSF samples were obtained at autopsy from 9 (5 males, 4 females) normal
control subjects and 9 (5 males, 4 females) AD subjects at short post-mortem intervals (PMI;
mean ± SEM, 3.12 ± 0.20 h). All specimens were immediately frozen in liquid nitrogen at the
time of autopsy and subsequently stored in a –70° freezer. All AD subjects demonstrated
progressive intellectual decline and met NINCDS-ADRDA Workgroup criteria for the clinical
diagnosis of probable AD (193). They also met accepted criteria for the histopathologic
diagnosis of AD (194,195). Control subjects, who underwent annual neuropsychological testing
as a part of our normal volunteer, longitudinal aging study, were without a history of dementia or
other neurological diseases and had mental status test scores in the normal range.
Neuropathologic evaluation of control brains showed only age-associated gross and
histopathologic alterations. The procedure used to collect the CSF samples was detailed
previously in an article by Lovell and Markesbery (159) The mean ± SEM Braak score was 1.3
± 0.2 for control subjects and 6.0 ± 0.0 for AD subjects. Demographic data for all subjects are
shown in Table 5.1. A pool of control CSF was generated by combining equal-volume aliquots
from each of the 9 control CSF samples.
Sample preparation began with an affinity-based procedure to remove the high
abundance of albumin and Ig. This method was similar to that of Wang et al. (160) and was
described in detail in the previous chapter. Briefly, 300 µL of Protein A/G Plus-Agarose beads
were placed into a Spin-X tube and washed twice with 500 µL of PBS. Rabbit anti-human
serum albumin antibody, 200 µL of a 50 µg/µL stock, was added to the beads in the Spin-X tube
along with 100 µL of PBS. Beads and antibody were incubated at room temperature for 30 min
with rocking. The Spin-X tube was centrifuged to remove fluid, and the beads were washed
three times with 500 µL of PBS. A 500-µL volume of raw CSF was added to the antibodybound beads in the Spin-X tube. CSF was incubated with the beads for 30 min at room
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Table 5.1. Subject demographic data.
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M
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0
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2
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F
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1
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1.66

2

F
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temperature with rocking. The processed CSF was collected in a clean 1.5-mL microcentrifuge
tube by centrifugation. The total protein content of the CSF was measured before and after
albumin/Ig removal using the bicinchoninic acid protein assay (BCA). This procedure was
performed for each of the 9 controls, 9 AD CSF samples, and for 18 aliquots of the pooled
control CSF (totaling 36 processed samples).
Labeling CSF with Cleavable ICAT Reagents

CSF samples were labeled with ICAT reagents following the general protocol included
with the Cleavable ICAT 10-Assay Kit with slight modifications. In general, aliquots containing
150 µg of total protein were removed from each control, AD, and pooled sample following
albumin/Ig removal. Aliquots were evaporated to dryness by vacuum centrifugation. Samples
were resuspended in 80 µL of 50 mM Tris and 0.1% SDS buffer (pH 8.5) and boiled in the
presence of tris(2-carboxyethyl)phosphine (TCEP) to reduce protein disulfide bonds. Each of
the 18 control and AD samples was incubated for 2 h at 37 °C with the heavy cleavable ICAT
reagent, while the 18 pooled control samples were incubated with the light cleavable ICAT
reagent. Once labeled, each heavy control and heavy AD sample was combined with a light
pooled control sample. Each control-pool and AD-pool mixture was then digested with trypsin.
Preliminary tests indicated that trypsin provided with the ICAT kit did not produce efficient
proteolysis of proteins. As such, 15 µL of 0.2 µg/µL Promega sequencing grade modified
trypsin was added to each heavy/light mixture and incubated for 12-16 h at 37 °C.
Following proteolysis, each peptide mixture was subjected to a solid phase extraction
(SPE) using a l mL C18 PrepSep tube. Though not specified in the manufacturer’s protocol, the
SPE step was added to remove salts from the digested CSF samples. (Note: It is known that CSF
contains high levels of salt, the presence of which may adversely affect the ability of peptides to
bind to the strong cation exchange (SCX) cartridge in the following step.) Once eluted from the
SPE tube with 400 µL of 75% I, the peptide mixtures were added to a SCX cartridge to remove
any remaining SDS, TCEP, and excess ICAT reagents. Next, the samples were purified on an
avidin cartridge, such that only ICAT-labeled, cysteine-containing peptides were retained and
selectively eluted from the cartridge. Once purified, all samples were evaporated to dryness by
vacuum centrifugation. Samples were resuspended in concentrated trifluoroacetic acid (TFA)
and incubated for 2 h at 37 °C to cleave the ICAT labels. Samples were once again dried by
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vacuum centrifugation. The dried ICAT samples were stored at –20 °C until 2-D LC-MS/MS
analysis, at which time they were reconstituted in 20 µL of 5% I containing 0.1% formic acid.
The general scheme for processing and labeling ICAT samples is illustrated in Figure 5.3.
Chromatography

Column packing and 2-D chromatographic procedures used in this study were very
similar to those detailed in Chapter 4. In short, a 2-D chromatographic was fabricated inlaboratory by packing 5 cm of 10-µm Partisil SCX material on top of 15 cm of 3-µm PolymerX
RP-1 reversed phase material in a single piece of 320 µm I.D. fused silica capillary. This was
done using a stainless steel pressure cell pressurized to 1200 psi with helium. Mobile phase was
delivered to the column at ~4 mL/min by an LC Packings Ultimate quaternary capillary LC
system (San Francisco, CA) equipped with a 20-µL injection loop. Each 2-D LC-MS/MS
analysis consisted of 13 chromatographic profiles. Each profile began with a salt step in which
0, 5, 10, 15, 20, 30, 40, 50, 100, 150, 225, 300, or 3000 mM ammonium acetate was passed over
the column to elute a fraction of ICAT peptides from the SCX phase. The salt step was then
followed by an organic gradient from 5-80% I to resolve the peptide fraction on the reversed
phase.
Mass Spectrometry

As ICAT peptides were separated on the 2-D LC capillary column, the effluent was
electrosprayed into a Finnigan LCQ Deca ion trap mass spectrometer (Thermo Finnigan, San
Jose, CA) for analysis. The electrospray source was operated at 4.0 kV of applied voltage with
43 arbitrary units of sheath gas flow, while the inlet capillary was held at 20.0 V and 170 °C.
Other mass spectrometer parameters were as follows: tube lens offset at –15.0 V, multipole 1
offset at –4.9 V, multipole 2 offset at –10.0 V, intermultipole lens at –55.0 V, entrance lens at –
66.0 V and trap DC offset at –10.0 V. Spectra of eluting CSF peptides were acquired in a datadependent fashion by first acquiring a full scan from m/z 150 to 2000 followed by a MS/MS scan
between m/z 150 and 2000 of the most intense ion of the previous full MS scan (35% normalized
collision energy, activation Q of 0.250, activation time of 30.0 ms). Once sampled, each MS/MS
precursor mass was excluded from further tandem experiments for three minutes. To construct
each analytical full and MS/MS scan, 3 full scans and 5 MS/MS scans were averaged,
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respectively. A maximum ion trap injection time of 300 ms was used for the full scans and 500
ms was used for MS/MS scans. The full scan and MS/MS automatic gain control (AGC) target
values were set at 5.0 x 107 and 2.0 x 107, respectively. These settings have been shown to be
optimal for proteomics applications (161).
Identification and Quantitation of ICAT Peptides

Acquired MS/MS spectra were subjected to protein database searches using
TurboSEQUEST, a component of Bioworks 3.1 software package (Thermo Finnigan, San Jose,
CA). However, to simplify the database searches, a few modifications were made to the protein
database and the search parameters of TurboSEQUEST, such that the algorithm was forced to
only search for ICAT-labeled, cysteine-containing peptides. To do this, a human sub-database of
the NCBI non-redundant protein database was compiled using the Fasta Database Utilities of
Bioworks. This human sub-database was then indexed to contain only tryptic, cysteinecontaining peptides. When performing searches of the indexed human database,
TurboSEQUEST search parameters were specified to look for a static modification of cysteine
residues that corresponded to 227.13 u, the mass of the light cleavable ICAT label. This required
all cysteines to have a light ICAT label. Additionally, a 9.03 u differential modification of
cysteine was also specified. In this way, the search algorithm also allowed for heavy ICAT
modifications (227.13 + 9.03 = 236.16 u) of cysteines. TurboSEQUEST results were filtered by
cross-correlation score (Xcorr) criteria. To be considered an unambiguous peptide identification,
the Xcorr had to be ≥ 1.8 for +1 peptides, ≥ 2.5 for +2 peptides, and ≥ 3.5 for +3 peptides.
Additionally, the difference between the first and second ranked cross-correlation scores
(DeltCN) for a peptide could not be less than 0.1.
Relative ratios of heavy/light (contol or AD/pool) peptides were obtained using the
XPRESS program of Bioworks 3.1. XPRESS was configured to quantify peptides having ICATmodified cysteine residues using the following parameters: a heavy/light mass difference of 9.0
u, a mass tolerance of 0.5 u, and a scan window of 100 scans. ICAT ratios for all tryptic peptides
identified from a protein were averaged to obtain the relative ratio of that protein.
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RESULTS AND DISCUSSION

In this study, the ventricular CSF proteomes of 9 control subjects and 9 AD subjects were
quantitatively evaluated using cleavable ICAT technology and 2-D LC-MS/MS. Subjects from
each population were indirectly compared through the use of a control pool. In other words,
each ICAT sample analyzed was comprised of CSF proteins from a control or AD subject
(labeled heavy) and CSF proteins from a pool of control subjects (labeled light). The use of
cleavable ICAT reagents allowed for the direct analysis of labeled samples by 2-D LC-MS/MS.
Quantitation of relative concentrations of proteins was achieved through the computation of
relative ion abundances of light/heavy ICAT peptide pairs observed in the full MS scan. Peptide
identification, on the other hand, was made possible by the data-dependent MS/MS analysis of
the ICAT mixtures.
The process of identification and quantitation can be better illustrated using an example
pair of ICAT peptides from this study. Figure 5.4 shows an MS scan acquired during the 2-D
chromatographic separation of an ICAT sample. The two most abundant ions represent a pair of
isotopically labeled CSF peptides. The ion of m/z 879.4 is a heavy ICAT-labeled peptide from
AD subject L, while the ion of m/z 874.9 is a light ICAT-labeled peptide from the pool. The m/z
of these two ions differ by 4.5, indicating that these peptides are doubly charged since the mass
difference between light and heavy ICAT labels is 9.0 u.
As the peptides eluted from the column, they were subjected to data-dependent MS/MS
analysis. In this case, each ion (m/z 874.9 and m/z 879.4) was selected by the instrument and
fragmented (Figure 5.5). These two MS/MS spectra were visually very similar in fragmentation
pattern, with several ions differing by m/z 9, further indicating that the precursor ions contain
heavy and light ICAT labels. It should be mentioned that it is not necessary to acquire an
MS/MS spectrum of both ions in an isotope pair. Since both peptides of an ICAT are identical in
amino acid composition, only one MS/MS spectrum is required for either ion to elucidate the
sequence of both peptides.
Once an ICAT sample was analyzed and MS data was acquired for all 13 cycles of the 2D LC run, the MS/MS spectra were searched against the indexed human database to identify
peptides from CSF proteins. Figure 5.6 shows the SEQUEST results obtained for the example
ICAT pair. Each was unambiguously identified as a tryptic peptide from human transferrin
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Figure 5.4. A full scan mass spectrum showing a light (m/z 874.9) and heavy (m/z 879.4) pair of
ICAT labeled CSF peptides eluting during a 2-D LC separation.
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Figure 5.5. MS/MS spectra for each peptide of the ICAT pair shown in Figure 5.4. Panel (a) is
the MS/MS of precursor m/z 874.9, and panel (b) is the MS/MS of precursor m/z 879.4
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Xcorr = 3.23
DeltCN = 0.5
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Xcorr = 3.8
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Figure 5.6. SEQUEST search results for the MS/MS spectra of an ICAT pair shown in Figure
5.5. Panel (a) is the MS/MS of precursor m/z 874.9, and panel (b) is the MS/MS of precursor m/z
879.4. In both cases, the sequence was unambiguously identified as FDEFFSEGCAPGSK, a
tryptic peptide of the human tranferrin protein (gi|4557871). In the sequence displayed on the
left, C and *C indicate that cysteine is identified as having a light and heavy ICAT labels,
respectively.
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(gi|4557871). By specifying a static cysteine modification of 227.13 u and a differential
modification of 9.03 u in the search parameters, the TurboSEQUEST algorithm properly
identified precursor m/z 874.9 as having a light ICAT label and precursor m/z 879.4 as having a
heavy ICAT label.
For each cysteine-containing peptide identified, XPRESS quantified the relative ratio of
heavy/light abundance. Figure 5.7 shows the XPRESS output for the transferrin peptide,
FDEFFSEGCAPGSK. By plotting the extracted ion chromatograms for each light and heavy
ICAT-labeled peptide and integrating the area under each peak, XPRESS reported a heavy/light
ratio of 1.25 for this peptide. In other words, the transferrin peptide was found to be 1.25 times
more abundant in the AD CSF sample from subject L, than in the pooled control sample. (Note:
For the purpose of this work, all ratios are expressed as heavy/light. In this manner, the ratios
are in terms of the control or AD sample relative to the pool.) This peptide was one of several
identified peptides belonging to transferrin. As such, ratios from all transferrin peptides were
averaged to obtain a heavy/light ratio of 1.96 for the entire transferrin protein. Two observations
of XPRESS should be noted. First, the program was designed such that TurboSEQUEST was
required to identify the peptide sequence before XPRESS would calculate ICAT ratios. This was
advantageous in that once the sequence is known, XPRESS could decide whether or not to look
for a light or heavy counterpart depending on whether or not the peptide contained a cysteine.
Effort was not wasted on trying to calculate ICAT ratios for peptides that did not have cysteines
or that failed to be identified. Second, and less fortunate, was the fact that XPRESS could not
handle large data sets as generated by 2-D chromatography. As such, each of 13 chromatograms
from 18 ICAT analyses (234 total chromatograms) was individually processed in XPRESS, and
the calculated ratios were manually transcribed into a Microsoft Excel spreadsheet.
The process just described for the transferrin peptide, FDEFFSEGCAPGSK, was the
method by which all MS/MS spectra were treated from all samples to identify and quantify
tryptic peptides from CSF. As a result, a total of 106 unique proteins were cumulatively
identified in this study. On average, 28 ± 10 proteins were identified per ICAT sample.
However, of these, only three proteins were unambiguously identified in all 18 subjects. These
proteins were transferrin, apolipoprotein D, and alpha-1-antitrypsin precursor. In light of the
sources of variability associated with the 2-D LC method as identified in Chapter 4, this was not
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Figure 5.7. Example of an output display from XPRESS. Show is the realative abundances of
light and heavy labeled human tranferrin peptide, FDEFFSEGCAPGSK. By plotting extracted
ion chromatograms for each peptide of the isotope pair and integrating the peaks, XPRESS
calculated a heavy/light ratio of 1.28.
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too surprising. Since the ICAT method considers only peptides that contain a cysteine, proteins
that contain only one or two cysteines (which is not atypical) have only one or two peptides on
which it can rely for identification. In the event that these one or two peptides produce a poor
quality MS/MS spectrum, are missed in a coelution of several peptides, or simply being below
the limit of detection, the associated protein will not be identified.
This variability between ICAT samples resulted in proteins that were identified in some
subjects, but not in others. As such, relative abundances of some proteins could not be
determined for all subjects, since XPRESS required peptide identification before quantitation
could be done. Table 5.2 illustrates this. Transferrin (gi|4557871) and alpha-1-antitrypsin
precursor (gi|1703025), two proteins that were identified in all subjects, obtained a heavy/light
ratio for all 18 samples. Pyruvate kinase, M2 isozyme (gi|125604) and prostaglandin D2
synthase (gi|32171249), on the other hand, were not identified in all samples, and therefore could
not be provided with a complete set of ratios. In some cases, extracted ion chromatograms were
manually plotted and integrated for peptides that were not identified. By this means, missing
ratios were obtained for some subjects, provided that the peaks of the extracted ion
chromatograms were not of abnormal shape due to weak ion signals.
To identify statistical differences between the control and AD populations for each
protein, the non-parametric Wilcoxon rank-sum test was employed. In short, for a given protein,
ratios from all samples (control and AD) were grouped. Those lacking quantitation were given a
ratio of zero. Samples were then ranked from 1-18 according to increasing heavy/light ratios
For samples having identical ratios, an average rank was given. Ranks for control and AD
samples were separately added together to produce a rank-sum for each population. With the aid
of a computer, P-values were generated and evaluated for the null hypothesis that the two
populations were the same. The two populations were considered statistically different if
P<0.02. Proteins for which there was a priori knowledge of possible differences in control and
AD populations, a P<0.05 could be considered to be statistically significant. As such, only uracil
DNA glycosylase (gi|35053) exhibited a statistically lower abundance in AD vs. control samples
(P = 0.02). Interestingly, the age-dependent deficiency of DNA glycosylases has recently been
implicated as a source for increased levels of oxidatively damaged mutagenic DNA (196).
Specifically, uracil DNA glycosylase is responsible for the repair of oxidative damage to
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Table 5.2. Example heavy/light (subject/pool) ratios.
Control Subjects
C D
E
F
G

A

B

0.76

3.70

0.80

1.19

0.93

0.62

5.00

0.94

0.61

0.54

0.88

1.64

1.45

1.41

1.75

H

I

J

K

L

AD Subjects
M N O

P

Q

R

Transferrin (gi|4557871)
1.41

0.65

1.52

0.53

1.30

0.46

1.19

1.23

0.53

0.95

1.19

1.29

0.88

0.43

1.89

1.32

0.55

0.61

1.43

3.13

1.05

1.09

1.03

0.30

Alpha-1-antitrypsin precursor (gi|1703025)
5.56

0.41

0.78

0.33

1.89

0.24

0.67

0.84

Pyruvate kinase, M2 isozyme (gi|125604)
0.82

0.83

0.98

1.69

1.03

0.79

1.06

1.69

2.33

Prostaglandin D2 synthase (gi|32171249)
0.47

0.57
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mutagenic uracil bases. It has been postulated that in mitochondria, the accumulation of DNA
damage contributes to a decline in tissue function (197).
Although this finding was interesting, there were other notable findings as a result of this
study. First was the fact that two of the proteins, apolipoprotein D and transferrin, found in all
18 subjects of this study were not found in all subjects of the control study described in Chapter
4. This could be explained by the amplifying nature of the ICAT method. Since ICAT only
utilizes cysteine-containing peptides, eliminating all other tryptic peptides from the sample
reduces much of the chemical noise. In theory, this should improve the detection of lower
abundance peptides.
More intriguing was the converse observation that 16 of the 20 proteins identified in all
10 of the control subjects in Chapter 4 were not identified in any of the subjects in this study. A
closer investigation revealed some plausible explanations. First, if a protein did not contain any
cysteine residues, it could not be labeled, and therefore would not be identified. Such was the
case with the protein osteopontin (gi|129260). Inspection of the amino acid sequence revealed an
absence of cysteines. This explained why osteopontin was found in all subjects of the previous
study but not in any subjects of this ICAT study.
Secondly, inefficient proteolysis may have resulted in the absence of many cysteinecontaining peptides. For instance, cystatin C (gi|14278690) and extracellular superoxide
dismutase 3 (gi|4507151) provide evidence (Figure 5.8). The arrows represent possible cleavage
sites for trypsin, while the shaded portion of the proteins represents the peptides that were
identified in the previous qualitative study. Of the identified peptides, none contain a cysteine
residue. This may be explained by inefficient cleavage of the proteins at sites that would have
generated cysteine-containing peptides. If the proteins were incompletely denatured or had
amino acid modifications that sterically hindered the activity of enzyme, then inefficient
proteolysis would have resulted.
Cysteine oxidation may also explain why some expected proteins were not identified in
this study. It is well known that oxidative stress increases with aging (198). It would be
expected then that the tissues utilized in this study would have considerable oxidation, as they
were obtained from elderly subjects. The oxidation of cysteines (e.g., to form a sulfenic acid,
sulfinic acid, sulfonic acid, persulfide, etc.) would block the reaction with ICAT reagents, thus
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Cystatin C (gi|14278690)
SPGKPPRLVGGPMDASVEEEGVRRALDFAVGEYNKASNDMYHSRALQVVRARKQIV
AGVNYFLDVELGRTTCTKTQPNLDNCPFHDQPHLKRKAFCSFQIYAVPWQGTMTLSK
STCQDA

Superoxide Dismutase 3
WTGEDSAEPNSDSAEWIRDMYAKVTEIWQEVMQRRDDDGTLHAACQVQPSATLDAA
QPRVTGVVLFRQLAPRAKLDAFFALEGFPTEPNSSSRAIHVHQFGDLSQGCESTGPHY
NPLAVPHPQHPGDFGNFAVRDGSLWRYRAGLAASLAGPHSIVGRAVVVHAGEDDLG
RGGNQASVENGNAGRRLACCVVGVCGPGLWERQAREHSERKKRRRESECKAA

Figure 5.8. Two proteins, cystatin C and superoxide dismutase 3, that were not identified in any
subjects in this study, but were identified in all subjects of the study described in Chapter 4.
Arrows indicate possible cleavage sites for trypsin, while the highlighted amino acids represent
peptides identified in the previous study. None of the highlighted regions contain cysteines,
which would have eliminated them from this ICAT study. In efficient proteolysis may explain
why no cysteine-containing peptides were identified for these proteins.
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eliminating that peptide from the experiment. Although we do not presently have definitive data,
experiments are currently being conducted to investigate this theory.
Lastly, during post-analysis investigation of the 2-D LC data, it was noticed that the
majority of peptides in each sample were identified in the chromatographic “breakthrough,”
rather than evenly distributed throughout all 13 organic cycles. Breakthrough is the term given
to peptides that, when loaded onto the 2-D column, bypass the SCX phase and elute during the
first organic gradient. For example, in one sample, 27% of the peptide identifications were made
from the first organic cycle. This indicated that peptides were not binding efficiently to the SCX.
A plausible explanation for this stems from the use of concentrated TFA to cleave the biotin tags
from ICAT labels. Although the samples were evaporated to dryness by vacuum centrifugation
following the cleaving step, it is likely that a population of trifluoroacetate anions remained.
Trifluoroacetate anions could conceivably ion-pair with the positive charges of protonated
peptides in the reconstituted samples, making them charge-neutral. As a result, peptides could
not bind to the sulfonic acid functional groups of the SCX.
CONCLUSIONS

A quantitative proteomics approach combining 2-D LC-MS/MS and cleavable ICAT
technology has been presented. This method was utilized for the purpose of comparing the
ventricular CSF proteomes of 9 neurologically normal, elderly subjects to those of 9 AD
subjects. Rather than directly comparing control and AD subjects, a pool of control CSF
samples was assembled to which each subject (control or AD) was individually compared. By
labeling subject and pool samples with heavy and light ICAT reagents, respectively, protein
identification and quantitation was simultaneously achieved through direct 2-D LC-MS/MS
analysis. A total of 106 unique proteins were cumulatively identified during this study, with an
average of 28 ± 10 proteins being identified per subject. Of the 106 proteins identified, only
three (transferrin, alpha-1-antitrypsin precursor, and apolipoprotein D) were identified in all 18
subjects. Quantitatively, only uracil DNA glycosylase was found to be statistically different
between the two populations (P = 0.02), having a lower abundance in AD subjects than control
subjects.
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CHAPTER SIX
CONCLUSIONS

Proteomics is a rapidly growing field of research aiming to understand dynamic
molecular and cellular processes through the global characterization of protein expression and
function. Advancements in proteomic technologies are largely driven by the need to perform
whole proteome analyses in a single experiment for the purpose of identifying protein alterations
corresponding to physiological changes or biochemical influences. As such, proteomics will
most likely find its greatest utility in various areas of medical research, including biomarker
discovery and drug development. Through global protein profiling, proteomics provides a means
to identify alterations in protein expression as a result of disease. The identification of diseasespecific markers may be achieved by comparatively characterizing proteins in biological fluids
(i.e., blood, urine, CSF, etc.) from both normal and diseased individuals. Additionally,
proteomics provides a tool for investigating protein interactions associated with disease-related
pathways by examining global changes in protein expression that result when cells or tissues are
treated with various drugs. One would expect that proteomics will significantly change the way
diseases are diagnosed, treated, or even prevented.
Proteomics applications such as biomarker discovery and drug development demand high
through-put processes due to the complexity and vast numbers of samples at hand. The
development of 2-D chromatographic methods, as the one described in this dissertation, have
stemmed from such needs. Though still in its infancy, 2-D chromatography is rapidly finding
utility in the proteomics community, as many research groups are beginning to realize its
advantages. Two-dimensional chromatography provides increased peak capacity capable of
resolving complex peptide mixtures, while requiring less sample preparation and manual labor
than traditional 2-D gel electrophoresis. Additionally, they are easily interfaced with mass
analyzers, such as quadrupole ion traps, through the use of electrospray ionization. With the aid
of modern computer algorithms, both in data acquisition (e.g., data-dependent algorithms) and
data analysis (e.g., database search algorithms), shotgun approaches to proteomics interrogation
of complex mixtures are becoming common practice.

115

This dissertation described the development of a 2-D LC-MS/MS method for bottom-up
proteomics analysis of complex protein samples. Through the use of a helium-pressurized
packing cell, the fabrication of 2-D biphasic (SCX and reversed phase) capillary columns was
achieved. This relatively simple method of producing capillary columns is very attractive in that
it provides a means of generating columns in-laboratory, thus avoiding costs of commercial
columns. Perhaps even more appealing, however, is the endless possibilities of custom column
fabrication. In fact, on could imagine packing numerous types stationary phases or even
combinations thereof to produce various forms of multidimensional columns. Three- or fourdimensional arrangements may not be out of the question, thus extending the peak capacity even
further.
As mentioned, global bottom-up analysis of complex protein samples is becoming almost
routine in the proteomics community. Surprising, however, is the fact that little attention is ever
given to mass spectral parameters governing the quality and quantity of spectra. In this work, for
example, it was illustrated that quadrupole ion trap parameters such as the number of averaged
scans and the ion injection times greatly affect not only the quality of MS/MS spectra, but also
the number of spectra that the data-dependent algorithm can acquire. Quality and quantity of
mass spectra are equally important in proteomic analysis of complex peptide mixtures, as low
quality spectra will produce ambiguous peptide matches and undersampling due to large duty
cycles will result in missing peptides eluting from the column.
In this work, the efficacy of the developed 2-D LC-MS/MS method was evaluated in the
proteomics analysis of human ventricular CSF. This method proved to be a promising approach
to the shotgun analysis of complex protein samples, as was demonstrated in the ability to identify
249 unique proteins from 10 neurologically normal subjects. One area of improvement,
however, was identified in the reproducibility of the 2-D LC-MS/MS method. In some cases, the
lack of reproducibility stemmed from peptide complexity of the samples, despite the invoking of
2-D separation. There was no question that the addition of a second orthogonal dimension to the
chromatographic method greatly enhanced the ability to resolve complex peptide mixtures;
however, by taking even smaller salt increments to elute fewer peptides from the SCX of
introducing a third dimension of separation, may further improve the analysis. This warrants
additional investigation.
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The field of proteomics is not only concerned with the identification of proteins in a cell,
tissue, or organism, but it also endeavors to quantify proteins. The determination of relative
abundances of proteins between control and altered states, can provide valuable insight to the
physiological processes occurring in the altered state. As such, a quantitative proteomics method
combining 2-D LC-MS/MS and cleavable ICAT technology was presented. A preliminary study
of control and AD ventricular CSF, indicated that this approach has much promise as a largescale, quatitative proteomics approach. Although ICAT labeling combined with 2-D LCMS/MS exhibited many attractive features, including the ability to simultaneously identify and
quantify CSF proteins between control and AD populations, it does, however, suffer from some
complications at this time. For example, the ICAT approach requires the isotope tagging of
proteins through the thiol groups of cysteine residues. This can be problematic when attempting
to analyze proteins lacking cysteines. Furthermore, to be most productive, the ICAT method
must be efficient at labeling the cysteines that are available. As seen in this work, proteins that
are not cysteine deficient are also occasionally not quantified as a result of inefficient labeling.
The lack of cysteine labeling is likely due to ineffective protein denaturing and digestion or
cysteine oxidation. In either case, these factors that affect the efficiency ICAT labeling warrant
further investigation in order to optimize global quantitation of complex protein mixtures.
Additionally, the current lack commercially available computer software capable of adequately
handling large ICAT data sets as generated by 2-D LC-MS/MS requires extensive manual
manipulation of the data, further reducing the productivity of large-scale protein identification
and quantitation.
The future of multidimensional LC MS/MS for global proteomic analysis appears to be
quite promising, as supported in this dissertation with the successful qualitative and quantitative
analysis of CSF. However, 2-D LC MS/MS does have its shortcomings and will not be able to
single-handedly tackle and solve all large-scale proteomics problems such as biomarker
discovery and drug development. Rather, a culmination of several techniques, including but not
limited to 2-D LC MS/MS, 2-D gel electrophoresis, and top-down approaches, will result in the
most productivity. The next several years should be very exciting as researchers apply and
integrate such proteomic techniques, as well as develop new ones, for the purpose of
understanding the role of proteins in diseases and discovering better ways to treat them.
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APPENDIX A

This table lists all 249 unique proteins cumulatively identified from 10 neurologically normal,
elderly subjects. Shown are GeneInfo Identification (GI) numbers, protein descriptions, protein
functions, subjects (A through J) in which the proteins were found, and the identified peptides for
each protein. For protein functions: M = metabolism, C = chaperone, Syn = protein synthesis, Sig
= signaling, Struc = structural, P = cell proliferation, D = defense, and U/O = unkown/other. All
identified peptides met the following SEQUEST cross-correlation score (XCorr) criteria: +1
peptides ≥ 1.8, +2 peptides ≥ 2.5, and +3 peptides ≥ 3.5. All peptides also had delta crosscorrelation scores (deltCN) of at least 0.1. (Note: M* indicates oxidized methionine, while S@
represents phosphorylated serine.)
GI
Number
gi|261970
gi|261745

Protein Description
serum amyloid A
isotype 1, SAA1
beta-trace

Funct
.
M

Subjects

Peptide Sequence

F

-.RGPGGAWAAEAISDAR.-

Sig

ABCDEFG
HIJ
ABDEFGHI
J

-.APEAQVSVQPNFQQDK.F

gi|178775

proapolipoprotein,
apolipoprotein A-I

M

gi|262838

cancer-associated
SCM-recognition
immunedefensesuppressing and
serine proteaseprotecting peptide,
CRISPP peptide
cyclophilin A

D

J

R.VKDLATVYVDVLK.D
K.DLATVYVDVLK.D
K.DSGRDYVSQFEGSALGK.Q
R.DYVSQFEGSALGK.Q
K.LLDNWDSVTSTFSK.L
R.EQLGPVTQEFWDNLEK.E
K.VEPLRAELQEGAR.Q
R.QKLHELQEK.L
K.LHELQEKLSPLGEEM*R.D
K.LSPLGEEMR.D
R.AHVDALR.T
R.THLAPYSDELR.Q
R.THLAPYSDELRQR.L
R.LAARLEALKENGGAR.L
K.ATEHLSTLSEK.A
K.AKPALEDLR.Q
R.QGLLPVLESFK.V
K.VSFLSALEEYTK.K
K.VSFLSALEEYTKK.L
K.VSFLSALEEYTKKLNTQ.K.FNXPFVFLM*IDQNTK.V

C

ABCDEFG

-.VNPTVFFDIAVDGEPLGR.V

gi|2981731
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HIJ

gi|1942682

hemoglobin

C

ACEFGHIJ

gi|178853

apolipoprotein E

M

ABCDEFG
HIJ

gi|319896

hemoglobin

C

ABCDEFG
HIJ

gi|1703025

alpha-1-antitrypsin
precursor

M

ABCDEFG
HIJ
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R.VSFELFADK.V
R.VSFELFADKVPK.T
R.ALSTGEKGFGYK.G
K.SIYGEKFEDENFILK.H
K.TEWLDGK.H
K.TEWLDGKHVVFGK.V
K.HVVFGK.V
K.VKEGMNIVEAM*ER.F
-.VHLTPEEK.S
-.VHLTPEEKSAVTALWGK.V
K.SAVTALWGK.V
K.VNVDEVGGEALGR.L
R.LLVVYPWTQR.F
K.VLGAFSDGLAHLDNLK.G
K.VVAGVANALAHKYH.K.SELEEQLTPVAEETR.A
R.ARLSKELQAAQAR.L
R.LSKELQAAQAR.L
R.GEVQAMLGQSTEELR.V
K.RLAVYQAGAR.E
R.LAVYQAGAR.E
R.ERLGPLVEQGR.V
R.LGPLVEQGR.V
R.VRAATVGSLAGQPLQER.A
R.AATVGSLAGQPLQER.A
R.TRDRLDEVKEQVAEVR.A
R.DRLDEVKEQVAEVR.A
R.AKLEEQAQQIR.L
R.LQAEAFQAR.L
R.LKSWFEPLVEDMQR.Q
R.LKSWFEPLVEDM*QR.Q
K.SWFEPLVEDMQR.Q
K.SWFEPLVEDM*QR.Q
K.VQAAVGTSAAPVPSDNH.-.VLSPADKTNVK.A
-.VLSPADKTNVKAAWGK.V
K.VGAHAGEYGAEALER.M
R.MFLSFPTTK.T
R.M*FLSFPTTK.T
K.TYFPHFDLSHGSAQVK.G
K.LRVDPVNFK.L
K.TDTSHHDQDHPTFNK.I
K.ITPNLAEFAFSLYR.Q
K.KQINDYVEK.G
K.KQINDYVEKGTQGK.I
K.QINDYVEKGTQGK.I

gi|2136119
8

serine (or cysteine)
proteinase inhibitor,
clade A

M

ABCDEFG
HIJ

gi|1427869
0

cystatin C

M

ABCDEFG
HIJ
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K.GKWERPFEVK.D
K.DTEEEDFHVDQVTTVK.V
R.LGMFNIQHCK.K
R.LGM*FNIQHCK.K
K.LSSWVLLMK.Y
K.LQHLENELTHDIITK.F
R.SASLHLPK.L
R.SASLHLPKLSITGTYDLK.S
K.LSITGTYDLK.S
K.SVLGQLGITK.V
K.VFSNGADLSGVTEEAPLK.L
K.AVHKAVLTIDEK.G
K.AVLTIDEK.G
K.FNKPFVFLMIEQNTK.S
K.FNKPFVFLM*IEQNTK.S
K.SPLFMGK.V
K.SPLFMGKVVNPTQK.K.SPLFM*GKVVNPTQK.K.VVNPTQK.K.TDTSHHDQDHPTFNK.I
K.ITPNLAEFAFSLYR.Q
K.KQINDYVEK.G
K.KQINDYVEKGTQGK.I
K.QINDYVEKGTQGK.I
K.GKWERPFEVK.D
K.DTEEEDFHVDQVTTVK.V
R.LGMFNIQHCK.K
R.LGM*FNIQHCK.K
K.LSSWVLLMK.Y
K.LQHLENELTHDIITK.F
R.SASLHLPK.L
R.SASLHLPKLSITGTYDLK.S
K.LSITGTYDLK.S
K.SVLGQLGITK.V
K.VFSNGADLSGVTEEAPLK.L
K.AVHKAVLTIDEK.G
K.AVLTIDEK.G
K.FNKPFVFLMIDQNTK.S
K.FNKPFVFLM*IDQNTK.S
K.SPLFMGK.V
K.SPLFMGKVVNPTQK.K.SPLFM*GKVVNPTQK.K.VVNPTQK.R.LVGGPMDASVEEEGVR.R
R.LVGGPM*DASVEEEGVR.R
R.LVGGPMDASVEEEGVRR.A

gi|4506251

prostaglandin D2
synthase

Sig

ABCDEFG
HIJ

gi|225985

amyloid related
serum protein SAA

M

ABEFGH

gi|229172

hemoglobin delta

C

AEFHIJ

gi|247143

serum amyloid A
protein beta

M

ABEFGH

gi|225986

amyloid related
serum protein SAA

M

ABEFGHJ

gi|443295

transthyretin

Sig

ABCDEFG
HIJ

gi|3915800

brain specific
polypeptide PEP-19
(Purkinje cell protein
4)
lipoprotein CIII

Sig

ABCEFIJ

M

BCDEGHI

gi|224917
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R.RALDFAVGEYNK.A
R.ALDFAVGEYNK.A
K.ASNDMYHSR.A
R.KQIVAGVNYFLDVELGR.T
K.QIVAGVNYFLDVELGR.T
R.WFSAGLASNSSWLR.E
K.KAALSMCK.S
K.SVVAPATDGGLNLTSTFLR.K
R.TMLLQPAGSLGSYSYR.S
R.TM*LLQPAGSLGSYSYR.S
R.TQTPRAELKEK.F
K.AQGFTEDTIVFLPQTDK.C
-.RSFFSFLGEAFDGAR.D
R.SFFSFLGEAFDGAR.D
R.EANYIGSDKYFHAR.G
R.LTGHGAEDSLADQAANK.W
-.VHLTPEEK.T
R.LLVVYPWTQR.F
K.VLGAFSDGLAHLDNLK.G
R.NFGKEFTPQMQAAYQK.V
K.VVAGVANALAHKYH.-.RSFFSFLGEAFDGAR.D
R.SFFSFLGEAFDGAR.D
R.EANYIGSDKYFHAR.G
K.RGPGGAWAAEVISDAR.E
-.RSFFSFLGEAFDGAR.D
R.SFFSFLGEAFDGAR.D
R.EANYIGSDKYFHAR.G
K.RGPGGVWAAEAISDAR.E
-.GPTGTGESKCPLMVK.V
-.GPTGTGESKCPLM*VK.V
K.CPLMVK.V
K.VLDAVR.G
R.GSPAINVAVHVFR.K
R.GSPAINVAVHVFRK.A
R.KAADDTWEPFASGK.T
K.AADDTWEPFASGK.T
K.VEIDTK.S
K.VQEEFDIDMDAPETER.A
K.VQEEFDIDM*DAPETER.A
R.AAVAIQSQFR.K
-.SEAEDASLLSFMQGYMK.H
-.SEAEDASLLSFM*QGYMK.H
-.SEAEDASLLSFMQGYM*K.H
-.SEAEDASLLSFM*QGYM*K.H
K.DALSSVQESQVAQQAR.G

gi|1105606
1

thymosin, beta 4

gi|339685

Struc

AEFHIJ

transthyretin

Sig

ABCDEFG
HIJ

gi|4503571

enolase 1

M

ABCDEFG
HIJ

gi|1195503

beta 2-microglobulin

M

ACDEFHIJ

gi|2136151

serum amyloid A2beta

M

ABEFGH

gi|1582662
9

peroxiredoxin 5

Sig

ABEF

gi|4507645

triosephosphate
isomerase 1

M

ABDEFHIJ
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K.NPLPSKETIEQEK.Q
K.NPLPSKETIEQEKQAGES.-.PLM*VKVLDAVR.G
K.VLDAVR.G
R.GSPAINVAVHVFR.K
R.GSPAINVAVHVFRK.A
R.KAADDTWEPFASGK.T
K.AADDTWEPFASGK.T
K.VEIDTK.S
R.GNPTVEVDLFTSK.G
R.AAVPSGASTGIYEALELR.D
K.AVEHINKTIAPALVSK.K
K.KLNVTEQEK.I
K.KLNVTEQEKIDK.L
K.LAMQEFMILPVGAANFR.E
K.LAM*QEFMILPVGAANFR.E
K.LAMQEFM*ILPVGAANFR.E
K.LAM*QEFM*ILPVGAANFR.E
R.IGAEVYHNLK.N
K.VVIGM*DVAASEFFR.S
R.SGKYDLDFKSPDDPSR.Y
R.YISPDQLADLYK.S
K.LAQANGWGVMVSHR.S
K.LAQANGWGVM*VSHR.S
R.IEEELGSK.A
R.IEEELGSKAK.F
R.NFRNPLAK.K.IQVYSRHPAENGK.S
R.IEKVEHSDLSFSK.D
R.VNHVTLSQPK.I
R.SFFSFLGEAFDGAR.D
R.EANYIGSDKYFHAR.G
R.GAEDSLADQAANKWGR.S
K.THLPGFVEQAEALK.A
K.THLPGFVEQAEALKAK.G
R.LLADPTGAFGK.E
K.ETDLLLDDSLVSIFGNR.R
K.RFSMVVQDGIVK.A
R.FSMVVQDGIVK.A
R.FSM*VVQDGIVK.A
R.KQSLGELIGTLNAAK.V
K.QSLGELIGTLNAAK.V
R.RHVFGESDELIGQK.V
R.HVFGESDELIGQK.V
K.VIADNVK.D
K.VVLAYEPVWAIGTGK.T

gi|6273483

latrophilin-2

gi|229149

hemoglobin beta

gi|7019519

Sig

BEJ

C

ACDEFGHI
J

Sig

ABCDEFG
HIJ

gi|4505591

proprotein
convertase
subtilisin/kexin type 1
inhibitor precursor;
granin-like
neuroendocrine
peptide precursor;
proSAAS
peroxiredoxin 1

Sig

AEFJ

gi|4502149

apolipoprotein A-II

M

ADEFIJ

gi|913159

neuropolypeptide h3

Sig

ABDFGHIJ

gi|2460318

RNA-binding protein
regulatory subunit

Syn

ABCEFGHJ

gi|114006

apolipoprotein A-IV
precursor

M

ADI
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K.TATPQQAQEVHEK.L
K.TATPQQAQEVHEKLR.G
K.SNVSDAVAQSTR.I
-.MTGNYLLTNPLLR.P
-.M*TGNYLLTNPLLR.P
-.VHLTPEEK.S
-.VHLTPEEKSAVTALWGK.V
K.SAVTALWGK.V
K.VDVDEVGGEALGR.L
K.VVAGVADALAHKYH.R.GLSAASPPLAETGAPR.R
R.SVPRGEAAGAVQELAR.A
R.ALAHLLEAERQER.A
R.ARAEAQEAEDQQAR.V
R.ILAGSADSEGVAAPR.R
K.IGHPAPNFK.A
K.KQGGLGPM*NIPLVSDPK.R
K.QGGLGPMNIPLVSDPK.R
K.QGGLGPMNIPLVSDPKR.T
R.TIAQDYGVLKADEGISFR.G
R.QITVNDLPVGR.S
K.VKSPELQAEAK.S
K.SPELQAEAK.S
K.SYFEKSKEQLTPLIK.K
K.SYFEKSKEQLTPLIKK.A
K.SKEQLTPLIK.K
K.SKEQLTPLIKK.A
-.PVDLSK.W
K.NRPTSISWDGLDSGK.L
K.GNDISSGTVLSDYVGSGPPK.G
K.LYEQLSGK.R.ALVILAK.G
K.GAEEMETVIPVDVMR.R
K.GAEEM*ETVIPVDVMR.R
K.GAEEM*ETVIPVDVM*R.R
K.VTTHPLAK.D
R.GPGTSFEFALAIVEALNGK.E
K.SELTQQLNALFQDK.L
R.LLPHANEVSQKIGDNLR.E
R.TQVNTQAEQLR.R
R.ENADSLQASLRPHADELK.A
K.LNHQLEGLTFQM*K.K
K.SLAELGGHLDQQVEEFR.R
K.ALVQQMEQLR.Q

gi|423038

pigment epithelialdifferentiating factor

P

ABDEFHIJ

gi|4505753

phosphoglycerate
mutase 1

M

ABCDEFG
HIJ

gi|31645

glyceraldehyde-3phosphate
dehydrogenase

M

ABCDEFG
HIJ

gi|129902

phosphoglycerate
kinase 1

M

ABCDEIJ

gi|2493359

transcription factor
BTF3 homolog
carbonic anhydrase II

Syn

CE

M

ABCEFGHI
J

apolipoprotein J

U/O

ABDEFGHI
J

gi|1151392
2

gi|178855

124

K.LAAAVSNFGYDLYR.V
R.ALYYDLISSPDIHGTYK.E
R.IKSSFVAPLEK.S
R.LDLQEINNWVQAQMK.G
R.LDLQEINNWVQAQM*K.G
K.TVQAVLTVPK.L
K.LKLSYEGEVTK.S
K.LQSLFDSPDFSK.I
K.ITGKPIKLTQVEHR.A
R.HGESAWNLENR.F
R.HYGGLTGLNKAETAAK.H
R.ALPFWNEEIVPQIK.E
R.VLIAAHGNSLR.G
K.AMEAVAAQGK.A
K.IISNASCTTNCLAPLAK.V
R.DGRGALQNIIPASTGAAK.A
R.GALQNIIPASTGAAK.A
K.VIPELDGKLTGMAFR.V
K.LISWYDNEFGYSNR.V
R.VVDLM*AHM*ASKE.R.FHVEEEGKGKDASGNK.V
K.LGDVYVNDAFGTAHR.A
R.AHSSMVGVNLPQK.A
R.AHSSM*VGVNLPQK.A
K.ALESPERPFLAILGGAK.V
K.YAEAVTR.A
K.ALMDEVVK.A
K.VSHVSTGGGASLELLEGK.V
K.ETIMNQEKLAKLQAK.V
R.QSPVDIDTHTAK.Y
K.AVQQPDGLAVLGIFLK.V
K.VGSAKPGLQK.V
K.VVDVLDSIK.T
K.SADFTNFDPR.G
K.YVNKEIQNAVNGVK.Q
K.EIQNAVNGVK.Q
K.TLIEKTNEER.K
K.TLIEKTNEERK.T
R.KTLLSNLEEAK.K
R.KTLLSNLEEAKK.K
R.ASSIIDELFQDR.F
R.ELDESLQVAER.L
K.LFDSDPITVTVPVEVSR.K
K.FMETVAEK.A
K.FM*ETVAEK.A

gi|1070613

actin alpha

gi|4502011

adenylate kinase 1

gi|8918224

Dickkopf-3

gi|4507895

vimentin

gi|1335059

fibroblast growth
factor
serum amyloid A4

transferrin

gi|1083509
5
gi|4557871

Struc

ACDEFGHI
J

P

AFJ

Sig

ABDEFGHI
J

Struc

GIJ

P

C

M

EI

C

ABDEFGHI
J
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K.FMETVAEKALQEYR.K
K.AGFAGDDAPR.A
R.AVFPSIVGRPR.H
K.DSYVGDEAQSK.R
K.YPIEHGIITNWDDMEK.I
R.VAPEEHPTLLTEAPLNPK.A
R.MQKEITALAPSTMK.I
R.M*QKEITALAPSTMK.I
R.MQKEITALAPSTM*K.I
R.M*QKEITALAPSTM*K.I
K.IIFVVGGPGSGK.G
K.YGYTHLSTGDLLR.S
K.GQLVPLETVLDMLR.D
R.EVEELMEDTQHK.L
R.EVEELM*EDTQHK.L
R.EVEELMEDTQHKLR.S
R.EVEELM*EDTQHKLR.S
R.SAVEEMEAEEAAAK.A
R.SAVEEM*EAEEAAAK.A
R.DQDGEILLPR.E
R.EVPDEYEVGSFMEEVR.Q
R.EPAAAAAALLGGEEI.R.TNEKVELQELNDR.F
R.FANYIDKVR.F
K.ILLAELEQLKGQGK.S
R.RQVDQLTNDKAR.V
R.KVESLQEEIAFLK.K
R.ISLPLPNFSSLNLR.E
R.DGQVINETSQHHDDLE.K.AILFLPLPVSSD.R.AYWDIMISNHQNSNR.Y
R.AYWDIM*ISNHQNSNR.Y
R.GPGGVWAAK.L
K.KDSGFQM*NQLR.G
K.DSGFQMNQLR.G
K.HSTIFENLANK.A
K.DKSKEFQLFSSPHGK.D
K.SKEFQLFSSPHGK.D
K.EFQLFSSPHGK.D
K.DSAHGFLK.V
K.DSAHGFLKVPPR.M
K.MYLGYEYVTAIR.N
K.M*YLGYEYVTAIR.N
K.KSASDLTWDNLK.G
K.SASDLTWDNLK.G

gi|1831450
0

cellular retinoic acid
binding protein 1

gi|7441428

actin gamma

gi|4502805

Sig

CDHJ

Struc

ABCDEFG
HIJ

chromogranin A;
parathyroid secretory
protein 1

Sig

DGHI

gi|120643

glyceraldehyde 3phosphate
dehydrogenase,
muscle

M

ACEFJ

gi|4507151

superoxide
dismutase 3,
extracellular

D

ABCDEFG
HIJ

gi|5454034

S100 calcium-binding
protein, beta

C

DF

gi|1713607
8

neuro-endocrine
specific protein VGF

Sig

ABCDEFG
HIJ

gi|35068

Nm23 protein

M

ABCFJ

gi|442908

Fk506 Binding

Sig

C
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K.SASDLTWDNLKGK.K
R.TAGWNIPMGLLYNK.I
R.TAGWNIPM*GLLYNK.I
K.HQTVPQNTGGKNPDPWAK.N
R.APNHAVVTR.K
K.YLGEEYVK.A
R.SSENFDELLK.A
K.VAVAAASKPHVEIR.Q
K.AGFAGDDAPR.A
R.AVFPSIVGRPR.H
K.DSYVGDEAQSK.R
R.VAPEEHPVLLTEAPLNPK.A
R.MQKEITALAPSTMK.I
R.M*QKEITALAPSTMK.I
R.MQKEITALAPSTM*K.I
R.M*QKEITALAPSTM*K.I
K.EEEEEMAVVPQGLFR.G
R.GGKSGELEQEEER.L
R.GGKSGELEQEEERLSK.E
K.SGELEQEEER.L
K.SGELEQEEERLSK.E
R.LEGQEEEEDNRDSSMK.L
R.EDSLEAGLPLQVR.G
K.VAHQLQALR.R
-.GKVKVGVDGFGR.I
K.IISNASCTTNCLAPLAK.V
K.VIPELDGKLTGMAFR.V
R.VVDLM*AHM*ASKE.R.VTGVVLFR.Q
R.YRAGLAASLAGPHSIVGR.A
R.AGLAASLAGPHSIVGR.A
R.AVVVHAGEDDLGR.G
K.AMVALIDVFHQYSGR.E
K.AM*VALIDVFHQYSGR.E
R.NSEPQDEGELFQGVDPR.A
R.VPERAPLPPPAPSQFQAR.M
K.THLGEALAPLSK.A
K.AYQGVAAPFPK.A
K.ARRPESALLGGSEAGER.L
R.RPESALLGGSEAGER.L
R.LLQQGLAQVEAGR.R
K.NAPPEPVPPPR.A
R.TFIAIKPDGVQR.G
R.VMLGETNPADSKPGTIR.G
R.VM*LGETNPADSKPGTIR.G
-.GVQVETISPGDGRTFPK.R

gi|2146597
0

Protein
kallikrein 6

M

ABEFHIJ

dopamine and
cAMP-regulated
neuronal
phosphoprotein 32
plasma retinolbinding protein

Syn

ABCDEFG
HIJ

C

ABEJ

insulin-like growth
factor II
Aldolase A

Sig

D

M

ABCDEFG
HIJ

glutamate
carboxypeptidaselike protein 2
secretory granule,
neuroendocrine
protein 1 (7B2
protein)

M

DE

Sig

ABCDEFG
HIJ

gi|5902726

peroxiredoxin 2

Sig

AEFJ

gi|4502599

carbonyl reductase 1

Sig

ABEFIJ

gi|2013891
2
gi|2066435
8

myotrophin (V-1
protein)
glutathione Stransferase

P

FJ

K.GPDGLTAFEATDNQAIK.A

Sig

ABCDEFHI
J

gi|4503377

P

C

gi|386984
gi|129260

dihydropyrimidinase
related protein-2
(DRP-2)
neuropeptide Y
osteopontin

-.PPYTVVYFPVR.G
-.PPYTVVYFPVRGR.C
K.FQDGDLTLYQSNTILR.H
K.TSPAKQQAPPVR.N
R.IVAPPGGRANITSLG.-

Sig
Struc

H
ABCDEFG
HIJ

gi|1237406

Cu/Zn-superoxide

D

AFHJ

gi|2173549
2
gi|2014166
7
gi|1335138
gi|229674

gi|2339649
7
gi|1352915
8

127

K.KPNLQVFLGK.H
R.QRESSQEQSSVVR.A
R.ESSQEQSSVVR.A
K.LSELIQPLPLER.D
K.KIQFSVPAPPSQLDPR.Q
K.IQFSVPAPPSQLDPR.Q
R.LSEHSSPEEEASPHQR.A
R.VKENFDKAR.F
R.FSGTWYAMAK.K
K.M*KYWGVASFLQK.G
R.GHVLAKELEAFR.E
-.PYQYPALTPEQK.K
-.PYQYPALTPEQKK.E
R.IVAPGKGILAADESTGSIAK.R
K.GILAADESTGSIAK.R
K.RLQSIGTENTEENR.R
R.ALQASALK.A
R.FRQELFR.M
R.MMAVAADTLQR.L
R.SVNPYLQGQR.L
R.SVNPYLQGQRLDNVVAK.K
K.KSVPHFSDEDKDPE.K.SVPHFSDEDKDPE.R.KEGGLGPLNIPLLADVTR.R
K.EGGLGPLNIPLLADVTR.R
R.QITVNDLPVGR.S
R.GQAAVQQLQAEGLSPR.F
R.FHQLDIDDLQSIR.A
R.VVNVSSIMSVR.A

R.SSPETLISDLLMR.E
K.AIPVAQDLNAPSDWDSR.G
K.SKEEDKHLKFR.I
K.FRISHELDSASSEVN.R.ISHELDSASSEVN.K.ESNGPVKVWGSIK.G

gi|4885063

dismutase
aldolase C

gi|4826898

R.TLVVHEK.A
R.IVAPGKGILAADESVGSMAK.R
R.IVAPGKGILAADESVGSM*AK.R
R.TPSALAILENANVLAR.Y
R.ALQASALNAWR.G
K.TFVNITPAEVGVLVGK.D
K.TFVNITPAEVGVLVGKDR.S
K.ALGHLDLSGNR.L
K.ALGHLDLSGNRLR.K
R.LHLEGNKLQVLGK.D
R.YLFLNGNK.L
R.VAAGAFQGLR.Q
R.ELQQAVLHMEQR.K
R.LPEVEVPQHL.K.MASGAANVVGPK.I
K.M*ASGAANVVGPK.I
R.LIADLGSTSITNLGFR.D
R.HRDTGILDSIGR.F
R.ASDYKSAHKGFK.G
K.KGVNLPGAAVDLPAVSEK.D
K.FGVEQDVDMVFASFIR.K
R.RFDEILEASDGIMVAR.G
R.APIIAVTRNPQTAR.Q
R.IATTTVTKGGIMLPEK.S

M

DEFHIJ

profilin 1

Struc

FJ

gi|1641846
7

leucine-rich alpha-2glycoprotein

U/O

ABEHIJ

gi|2007022
8

nucleobindin 1

C

EH

gi|7661714

predicted osteoblast
protein

U/O

AEFH

gi|1070625

myelin basic protein

P

C

gi|107554

pyruvate kinase

M

ABCDEFIJ

gi|1743987
2
gi|4557581

similar to CPN10-like
protein
fatty acid binding
protein 5

C

CEGI

M

BF

gi|179151
gi|4507113
gi|4503143

antithrombin III
synuclein, gamma
cathepsin D
preproprotein

M
Struc
M

A
EI
ABEFJ

gi|2204984
1
gi|4507243
gi|4885413

hypothetical protein
XP_175069
somatostatin
histidine triad
nucleotide binding
protein 1
matrix Gla protein
insulin-like growth
factor binding protein
7

U/O

D

K.ELGVGIALRK.M
R.IYEKVE.K.LQPLDFKENAEQSR.A
K.TKENVVQSVTSVAEK.T
R.QVFGEATKQPGITFIAAK.F
K.FDGILGMAYPR.I
R.ISVNNVLPVFDNLMQQK.L
R.ISVNNVLPVFDNLM*QQK.L
-.MLSYPGKAPILASLSGSTR.V

Sig
M

J
ABCDFIJ

K.SLAAAAGKQELAK.Y
K.AQVARPGGDTIFGK.I

Struc
Sig

IJ
ABEFHIJ

Sig

ADEFHIJ

R.NANTFISPQQR.W
R.TELLPGDRDNLAIQTR.G
K.ITVVDALHEIPVK.K
K.ITVVDALHEIPVKK.G
K.HLEEPGETQNAFLNER.K
R.KQASAIKKEELVAR.S
R.SSQGGSLPSEEK.G
K.GYPGVQAPEDLEWER.Y

gi|4505179
gi|4504619|

gi|4502807

chromogranin B
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|4557237
gi|2204450
8
gi|1942977
gi|2056092
5
gi|7341255

gi|3983127

gi|3005715
gi|6912328
gi|3402145

gi|1176162
9

gi|1339978
0
gi|2829415

gi|4758086
gi|1264400
8
gi|2174859
2
gi|5031851
gi|4502605
gi|5803011

M

AJ

K.ELENLAAMDLELQK.I
K.ELENLAAM*DLELQK.I
R.TPIGSFLGSLSLLPATK.L

U/O

E

-.M*FVSSLPVVQSVRS@R.E

D

B

-.M*PM*FIVNTNVPR.A

Sig

ABEFIJ

K.LGTQHPESNSAGNDVFAK.F

Sig

ABCEFIJ

K.TQSSLVPALTDFVR.S

D

CDEGJ

Struc
Sig

C
ABCEGHI

R.RLTVGAAQVPAQLLVGALR.V
R.LTVGAAQVPAQLLVGALR.V
R.AFPALTSLDLSDNPGLGER.G
R.VVVHKETELAEEGED.R.ALPESLGQHALR.S
R.AERQHQLYVGVLGSK.L

D

F

R.STDYGIFQLNSR.Y

D

AEHIJ

D

ABCDEFG
HIJ

K.M*KPVPDLVPGNFK.S
R.MELERPGGNEITR.G
R.HRHPDEAAFFDTASTGK.T
K.ESSSHHPGIAEFPSR.G
-.PMFIVNTNVPR.A
-.PM*FIVNTNVPR.A

Sig

AEHI

cysteine and glycinerich protein 1
UMP-CMP kinase

Sig

CFHJ

R.AALEGFLAALQADPPQAER.V
R.HYQHVAAVDPEK.A
K.GGLQPPDSKDDTPMTLPK.G
K.MNPLEQYER.K
K.M*NPLEQYER.K
K.GFGFGQGAGALVHSE.-

M

B

K.SVDEVFDEVVQIFDKEG.-

FLJ00373 protein

U/O

B

R.M*DGEGQLTLTGQLGDVMK.E

stathmin 1
cholecystokinin
gamma enolase

Struc
Sig
M

C
H
ABCDEFG
HIJ

R.ASGQAFELILSPR.S
K.NLQNLDPSHR.I
R.AAVPSGASTGIYEALELR.D
K.LAMQEFMILPVGAESFR.D

acetyl-CoA
acetyltransferase 1
hypothetical protein
XP_174457
macrophage
migration inhibitory
factor
similar to Chloride
intracellular channel
protein 4
brain
acetylcholinesterase
putative membrane
anchor
monocyte antigen
CD14 precursor
protein 4.1-G
dimethylarginine
dimethylaminohydrol
ase 1
Contribution Of
Hydrophobic Effect
To The
Conformational
Stability Of Human
Lysozyme
fibrinogen, alpha
chain

macrophage
migration inhibitory
factor
amyloid precursorlike protein 1
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gi|4826762

haptoglobin

D

ADI

gi|1404314
5

LIM and SH3 protein
1

C

FJ

gi|5031635
gi|229323
gi|1744055
4

cofilin 1
haptoglobin alpha2
similar to peptidylPro cis trans
isomerase
glutathione
transferase omega
ferritin, heavy
polypeptide 1
gelsolin

Struc
D
C

A
ADEGHIJ
J

Sig

J

R.SLGKGSAPPGPVPEGSIR.I

C

A

K.NVNQSLLELHK.L

Struc

ADEFHIJ

gi|4758484
gi|4503795
gi|4504165

R.ILGGHLDAK.G
R.HYEGSTVPEKK.T
K.VTSIQDWVQK.T
R.LKQQSELQSQVR.Y
K.GKGFSVVADTPELQR.I
K.LGGSAVISLEGKPL.K.NPANPVQ.R.VKEGM*DIVEAMER.F
R.VKEGM*DIVEAM*ER.F

gi|1507934
8

angiotensinogen

Sig

ACDEFGHI
J

gi|2221926
7

vitamin D-binding
protein

D

ADE

gi|1562078
0

glutamate
carboxypeptidase

Sig

J

gi|2206745
6
gi|2053787
4
gi|871360

similar to brain
specific protein
hypothetical protein
XP_119790
A4 amyloid protein
precursor

U/O

E

K.TASDFITK.M
K.QTQVSVLPEGGETPLFK.Q
R.AVEVLPK.A
K.TPSAAYLWVGTGASEAEK.T
R.RTPITVVK.Q
K.ANAGKPKDPTFIPAPIQAK.T
K.PKDPTFIPAPIQAK.T
K.DPTFIPAPIQAK.T
K.QPFVQGLALYTPVVLPR.S
K.VM*DKYTFELSR.R
R.RTHLPEVFLSK.V
K.AKLPDATPTELAK.L
K.LPDGSEIPLPPILLGR.L
R.YPSLSLHGIEGAFSGSGAK.T
K.SVTGTDVDIVFSK.V

U/O

AEF

R.M*SQDQEHS@QPEQ.-

Sig

AFHI

gi|4504067

aspartate
aminotransferase 1

M

ABEJ

gi|2153628
6

creatine kinase B

M

ADJ

gi|2048321
7

similar to
mitochondrial import
receptor subunit
TOM20 homolog
ubiquitin precursor

C

F

R.ISYGNDALMPSLTETK.T
R.GLTTRPGSGLTNIK.T
K.RVGGVQSLGGTGALR.I
R.VGGVQSLGGTGALR.I
K.NLDYVATSIHEAVTK.I
K.VLTPELYAELR.A
R.LGFSEVELVQMVVDGVK.L
K.YTKPLLSDTEQEVQAR.N

Sig

EI

Sig

D

gi|2118964
gi|9507245

tyrosine 3monooxgenase/trypt
ophan 5monooxgenase
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R.LIFAGK.Q
K.IQDKEGIPPDQQR.L
R.NLLSVAYKNVVGAR.R

gi|1857838
8
gi|117558

activation protein
(14-3-3 protein)
60S ribosomal
protein L13a
macrophage colonystimulating factor

Syn

G

-.M*CNS@KEIQEKLSTR.H

D

HIJ

Struc

AE

C

ABEFJ

R.SHSSGSVLPLGELEGR.R
R.SPAEPEGGPASEGAARPLPR.F
K.SLEDLQLTHNK.I
R.LKEDAVSAAFK.G
R.LGGPEAGLGEYLFER.L

gi|4505047

lumican

gi|2014949
8
gi|1855221
7
gi|2161449
9

ferritin, light
polypeptide
hypothetical protein
XP_103921
villin 2

U/O

F

R.VLVLKS@HRM*K.N

Struc

AEF

gi|139653

vitronectin precursor

Sig

ADEJ

gi|1132156
1

hemopexin

C

ADE

gi|1340142

alpha1antichymotrypsin

C

ADGI

gi|5802984

beta-1,3-Nacetylglucosaminyltra
nsferase
microtubuleassociated protein
tau
insulin-like growth
factor binding protein
6
secretogranin III

M

AEI

K.SQEQLAAELAEYTAK.I
R.QLLTLSSELSQAR.D
R.THNDIIHNENMR.Q
R.THNDIIHNENM*R.Q
R.DWHGVPGQVDAAMAGR.I
R.DWHGVPGQVDAAM*AGR.I
R.IYISGMAPRPSLAK.K
R.IYISGM*APRPSLAK.K
R.WKNFPSPVDAAFR.Q
K.SGAQATWTELPWPHEK.V
R.LYGSEAFATDFQDSAAAK.K
R.NLAVSQVVHK.A
R.SVDQVKAQLR.T
R.TALASGGVLDASGDYR.V

Struc

FJ

K.PVDLSK.C
K.IGSLDNITHVPGGGNK.K

Sig

ABFHIJ

R.HLDSVLQQLQTEVYR.G

Sig

ADEIJ

U/O

A

K.AITEKEKIEK.E
K.AITEKEKIEKER.Q
R.SSPLDNKLNVEDVDSTK.N
R.KEVELGAGVGGSPERNR.G

Syn
Sig
Sig
Syn

BFHI
H
BGJ
J

K.DAEEDDSLANSSDLLK.E
R.SILAAIGAYPLSR.K
-.MKLGSPKSSVTIWQPLK.L
R.ALRETLPAEQDLTTK.N

U/O

I

R.SEAAAVQPVIGISQR.V

Sig

AHI

K.HIQETEWQSQEGK.T
K.TGLEAISNHKETEEK.T
R.AQSIAYHLK.I

gi|8400713
gi|1132159
3
gi|1955764
5
gi|2083419
4
gi|5453876
gi|7656955
gi|88209
gi|4506179
gi|1641838
9
gi|2339686
1

similar to
hypothetical protein
FLJ11294
proenkephalin
calcyon
N-chimerin
proteasome subunit
alpha type 1
hypothetical protein
MGC17330
hevin
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gi|7524354
gi|2007079
5
gi|2136149
5
gi|2136112
2
gi|1548933
9
gi|1855247
4
gi|1513153
5
gi|1630655
0
gi|189238
gi|2153644
9
gi|5174539
gi|4505417
gi|1458585
5
gi|4759140
gi|4505025
gi|7661704
gi|2054788
1
gi|1401797
3
gi|4758194
gi|2053508
1
gi|4557032
gi|1395901
8
gi|4885245

dimethylarginine
dimethylaminohydrol
ase 2
formin binding
protein 3
PTD012 protein
LIM protein FHL-1
Similar to RIKEN
cDNA 2610528G05
gene
hypothetical protein
XP_103974
adipsin/complement
factor D precursor
selenium binding
protein 1
neuroleukin (glucose6-phosphate
isomerase)
prefoldin 1
malate
dehydrogenase
quinone
oxidoreductase 2
phosphatidylethanola
mine binding protein
solute carrier family 9
(sodium/hydrogen
exchanger)
limbic systemassociated
membrane protein
osteoglycin
preproprotein;
mimecan
hypothetical protein
XP_094625
KIAA1878 protein
serine/threonine
kinase 17b
(apoptosis-inducing)
similar to Cop-coated
vesicle membrane
protein p24 precursor
lactate
dehydrogenase B
endothelial cellselective adhesion
molecule
FOS-like antigen 2

Sig

J

R.DFAVSTVPVSGPSHLR.G

Struc

A

R.RRTLLEQLDDDQ.-

U/O

BCEFJ

R.IAEVGGVPYLLPLVNQK.K

P

J

R.FVFHQEQVYCPDCAK.K

U/O

AE

R.LAGLGLQQLDEGLFSR.L
R.SLTLGIEPVSPTSLR.V

U/O

EF

R.KACRLESLQKELLSK.V

D

G

R.VASYAAWIDSVLA.-

U/O

DJ

R.TKLVLPSLISSR.I

M

A

K.ILLANFLAQTEALMR.G

C

AF

R.EM*LMAR.R

M

BFJ

K.ELTEEKESAFEFLSSA.-

M

F

K.VLIVYAHQEPK.S

Sig

F

R.YQFFVYLQEGK.V

Sig

AF

R.EALAEAALESPRPALVR.S

P

AHI

R.EFEGEEEYLEILGITR.E

P

H

K.NIKEKETVIIPNEK.S

U/O

F

K.NTVFQFGWNLEGLK.R

U/O

C

P

A

R.SGPGPGLGSGSTSGPADSVM*R.
Q
K.IVDFGM*SRKIGHACELR.E

Sig

J

R.VSFELFADEVPK.T

M

BCDEG

K.SADTLWDIQKDLKDL.-

Sig

FJ

R.QLPSFQTFFAPALDVIR.G

Syn

H

R.RDEQLSPEEEEKRR.I
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gi|4507171
gi|2014961
7
gi|4502719
gi|1105604
6
gi|1598258
6
gi|6466466
gi|1849091
7

osteonectin
neural proliferation,
differentiation and
control, 1 (NPDC-1)
cadherin 13
nectin-like protein 1;
TSLC1-like 1; brain
immunoglobulin
receptor precursor
KIAA0100 protein
RAN binding protein
3
secretogranin II
(chromogranin C)

P
P

AJ
BDEHI

R.LEAGDHPVELLAR.D
R.LEDEIDFLAQELAR.K

Sig

AHI

D

AEHJ

R.TPHAEDMAELVIVGGK.D
R.SIVVSPILIPENQR.Q
K.SLVTVLGIPQKPIITGYK.S

U/O

I

K.ANLQLESEELNILIR.C

C

E

K.FVFGQNMSERVLSPPK.L

Sig

EF

R.LENVQKFPSPEMIR.A
K.RLVNAAGSGR.L
R.VYHVGLGDAAQPR.N

gi|1413324
5
gi|4557385

KIAA1247 protein

U/O

HI

complement
component 3 (C3)
precursor

D

ADEFHIJ

gi|4506975

solute carrier family
12
(sodium/potassium/c
hloride transporters)
alpha-2-antiplasmin
precursor
similar to
evidence:NAS~hypot
hetical
protein~putative
alpha1 syntrophin
neuronal pentraxin
receptor
extracellular matrix
protein 1
hypothetical protein
MGC40368
similar to Heat shock
protein HSP 90-beta
fibrinogen alphaA
CD81 partner 3

Sig

BFH

M

CDIJ

R.QLTSGPNQEQVSPLTLLK.L

U/O

I

K.QREALLPPVTPQTSCR.Q

Struc
M

F
AEHI

R.KADAGGLGISIKGGRENK.M
R.VAELEHGSSAYSPPDAFK.I

U/O

H

K.EVGPPLPQEAVPLQK.E

U/O

CH

R.QSFASDSSSK.S

C

I

K.KKMEESKEK.F

D
D

BCDEGHJ
A

-.ADSGEGDFLAEGGGVR.G
R.VLPDVLQVSAAPPGPR.G

Struc
Sig
Syn

ADI
EI
A

R.AVFVDLEPTVIDEVR.T
K.AASQPGELKDWFVGR.S
R.TITGCIPESLRNCVNK.E

M

ABEFGIJ

R.VGPVAATYPMLNK.K
R.VGPVAATYPM*LNK.K

gi|112907
gi|2054210
8
gi|1588680
gi|1740288
8
gi|1270757
2
gi|2274951
7
gi|1615790
1
gi|223918
gi|1644502
9
gi|6755901
gi|6429043
gi|2055829
0
gi|7705558

tubulin alpha chain
carboxypeptidase E
similar to C-terminal
binding protein 2
myo-inositol 1phosphate synthase
A1
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K.RIPIEDGSGEVVLSR.K
K.LSINTHPSQKPLSITVR.T
R.TKKQELSEAEQATR.T
R.SVQLTEK.R
R.ASHLGLAR.S
R.VELPGTAVPSVPEDAAPASR.D
R.AAAAAAAAAAAAAAAGAGAG
AK.Q

gi|279675

A1
similar to PR/SET
domain containing
protein 07
sialic acid binding Iglike lectin 7; adhesion
inhibitory receptor
molecule 1, siglec-7
natural killer cellspecific antigen
KLIP1
fibronectin precursor

gi|319924

cadherin 2

Sig

AEFHI

gi|1849068
2

fibulin 1

Sig

AE

gi|1842691
1

protein tyrosine

D

ADEH

R.VTWAPPPSIDLTNFLVR.Y
R.FLATTPNSLLVSWQPPR.A
R.VPGTSTSATLTGLTR.G
R.GATYNIIVEALKDQQR.H
K.DVHEGQPLLNVK.F
K.FLIYAQDKETQEK.W
R.KVSPHSGVVALTKPVPEPR.D
K.VSPHSGVVALTKPVPEPR.D
R.AKPSAPVVSGPAAR.A

U/O

I

K.KTPNKGLVQVTTHR.L

U/O

H

K.SRIALNSAK.L

Struc

CDEFGHJ

solute carrier family 6
(neurotransmitter
transporter, GABA)
leucine
aminopeptidase
complement C4
precursor

Sig

B

K.STGGISVPGPM*GPSGPR.G
K.SGDRGETGPAGPAGPVGPVGAR.
G
R.ERIRQLMCPAEDLPQR.N

M

F

K.LRETLNISGPPLK.A

D

ABDEGHI

eukaryotic initiation
factor 4B
H+-transporting
ATPase
chondroitin sulfate
proteoglycan 5
(neuroglycan C)
KIAA1826 protein

Syn

J

R.TTNIQGINLLFSSR.R
R.GHLFLQTDQPIYNPGQR.V
R.YIYGKPVQGVAYVR.F
R.AASIFGGAKPVDTAAR.E

M

C

K.RTALVANTSNMPVAAR.E

Sig

I

R.EAGSAVEAEELVK.G

U/O

A

K.RRLDIEAER.L

similar to RU2S

U/O

H

K.RTGAVPLNPSVDSSGRSR.G

reticulon 1;
neuroendocrine-

Sig

C

K.GATPAPQAGEPSPGLGAR.A

gi|2098458
4
gi|7657570

gi|2038503
0

gi|1469882
gi|2047844
9
gi|4502945

gi|2136158
1
gi|7705688
gi|2014117
1
gi|1814661
4
gi|1991342
4
gi|5729788
gi|1401786
9
gi|2089333
5
gi|1086393
5

phosphatase, nonreceptor type
substrate 1
KIAA0150 gene
product
hypothetical protein
XP_114657
alpha 1 type I
collagen
preproprotein

Syn

H

R.DKGILPNR.R

Sig

J

R.M*EKGNIKWNYK.Y

D

H

R.DIPAMLPAAR.L

Sig

ABEFGHIJ
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gi|1352220
gi|462325
gi|1751121
3
gi|2205918
4
gi|1414117
0
gi|2173992
5
gi|2497301
gi|7022719
gi|1854371
4
gi|4503635
gi|2089341
1
gi|2342852
4
gi|553204
gi|2033624
4
gi|2204647
6
gi|2086069
8
gi|2007023
0
gi|1731856
9
gi|1521530
8
gi|2136175
3
gi|107082
gi|5729767
gi|5052951

specific protein
histidine
decarboxylase
heat shock 70 kDa
protein 1
tumor endothelial
marker 7-related
precursor
similar to aristalessrelated homeobox
protein ARX
metastasisassociated 1-like 1
protein
hypothetical protein
contactin 1 precursor
unnamed protein
product
similar to transcript Y
7
coagulation factor II
precursor;
prothrombin
similar to KIAA0420
evin1
amyloid beta (A4)
precursor-like protein
2
proprotein
convertase
subtilisin/kexin type 2
similar to homeobox
protein NKX2-6
similar to KIAA1593
protein
ectonucleotide
pyrophosphatase/ph
osphodiesterase 2
(autotaxin)
cytokeratin 1
similar to
dystroglycan 1
protein kinase C
binding protein 1
microtubuleassociated protein 4
cell adhesion
molecule with
homology to L1CAM
unknown protein

M

IJ

R.LFLIPATIQDKLIIR.F

C

A

K.NQVALNPQNTVFDAK.R

C

H

R.ASVGQDSPEPR.S

P

D

K.PSLRGPASARALCPLPR.R

Syn

D

R.NQLSQNRGLGGIMVK.R

U/O

AI

K.NEVQLNAYVLQEPPK.G

Sig
U/O

A
F

R.IKTDGAAPNVAPSDVGGGGGR.N
K.IS@ENM*SLQFENQMNK.T

U/O

E

R.IKSQDDGGVPPYNVK.Y

D

BDG

R.TATSEYQTFFNPR.T

U/O

F

R.KIAGVEHVVFIQR.N

C

ADFH

R.LYDLELDPTALEEEEK.Q

Sig

H

R.VGGLEEERESVGPLR.E

Sig

G

K.EELEEELDEAVER.S

U/O

E

R.HINASPADKALGR.R

U/O

H

K.LLKRKPSLDDLK.E

P

A

K.VNSMQTVFVGYGPTFK.Y

Struc

I

R.SLDLDSIIAEVK.A

Struc

E

R.LFDMSAFMAGPGNAK.K

Sig

J

R.LIAEVKKQLELEK.Q

Struc

J

K.VGSLDNVGHLPAGGAVK.T

Sig

AFHI

K.THPVEVFEPGAEHIVR.L

U/O

G

K.AMATKTKIDKWDLIK.L
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gi|1070458
gi|9910376
gi|1343219
2
gi|2012760
5
gi|4759044
gi|1269796
7
gi|1160296
3
gi|3043584
gi|2135871
gi|1421153
6
gi|4503355
gi|2089062
0
gi|2362002
9
gi|1786409
2

ferroxidase
inner centromere
protein
inter-alpha-trypsin
inhibitor family heavy
chain-related protein
chondroitin sulfate
proteoglycan
BEHAB/brevican
Rho-associated,
coiled-coil containing
protein kinase 2
KIAA1711 protein

Sig
P

A
D

K.GAYPLSIEPIGVR.F
R.EFSKEPELM*PK.T

M

ADEH

R.MNFRPGVLSSR.Q

Sig

AEHI

R.ALHPEEDPEGR.Q

Sig

D

R.LEKTAKELEEEITLR.K

U/O

J

K.ELVSRELKDWPK.K

heparan sulfate
proteoglycan
perlecan

Sig

AEI

KIAA0530 protein
DNA replication
licensing factor
MCM5
neurexin 2

U/O
P

G
A

R.RGSIQVDGEELVSGR.S
R.SPGPNVAVNAK.G
K.GSVYIGGAPDVATLTGGR.F
K.FLEESAVKQKKNTDK.D
R.RFKEFLR.Q

Sig

E

K.LGERPPALLGSQGLR.G

dedicator of cytokinesis 1
similar to KIAA0335

Sig

F

R.QLYVQDNREMFRSVR.H

U/O

I

R.DFDTLIETFKAK.E

U/O

A

R.YRGNGDK.Q

Struc

G

R.AEM*EILPKPWR.K

similar to
hypothetical protein
axonemal dynein
heavy chain 7
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